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Abstract 
Investigating the Role of Toll-like Receptors in Juvenile-onset 
Systemic Lupus Erythematosus 
Colin Thorbinson 
Background: Juvenile-onset Systemic Lupus Erythematosus (JSLE) is a chronic debilitating 
multi-system autoimmune condition characterised by auto-antibody production directed 
against nuclear antigens. It is associated with a more severe onset and more aggressive 
clinical course than in adults, with poor prognostic markers presenting earlier in childhood. 
It has been proposed that dysregulated neutrophil apoptosis may be a source of 
autoantigen in JSLE. Toll-like Receptors (TLRs) are essential in the function of the innate 
immune system recognising pathogenic material. Upon stimulation they initiate a non-
specific immune response leading to the production of an antigen-specific immune defence 
and autoantibody production. TLRs have been implicated in the development of 
autoimmunity. TLRs 3, 7, 8 & 9 are capable of recognising nucleic autoantigens typical of 
SLE and their expression has been shown to positively correlate with anti-dsDNA titres and 
disease activity in adult-onset SLE. To date there have been no studies examining the role 
of TLRs in JSLE. 
Aim: To assess whether apoptotic neutrophils in JSLE are providing a source of nuclear 
autoantigen which are being detected through TLRs 3, 7, 8 & 9 resulting in an inflammatory 
response through activation of an adaptive autoimmune response. 
Methods: Peripheral Blood Mononuclear Cells (PBMC’s) and B cells were isolated from JSLE 
patients, Juvenile Idiopathic Arthritis (JIA) (inflammatory controls) and non-inflammatory 
controls.  TLR 3, 7-9 mRNA and protein expression was measured using quantitative PCR 
(qPCR) and flow cytometry respectively. PBMCs were incubated with TLR agonists, 
activation was measured by IFN-α protein and mRNA expression, by ELISA and qPCR 
respectively. Neutrophils were isolated from healthy controls and incubated with JSLE 
serum to induce apoptosis. Apoptotic neutrophils were incubated with PBMCs at varying 
concentrations for 6 hours. After which IFN-α mRNA expression was measured by qPCR.  
PBMCs were treated with a MyD88 inhibitor to block TLRs 7-9 or left untreated. MyD88 
treated and untreated PBMCs were incubated with TLR9 agonist or apoptotic neutrophils 
for 6 hours. TLR activation was measured using IFN-α mRNA expression by qPCR.  
Results: JSLE patients have a significantly increased PBMC TLR 3, 8 and 9 protein and mRNA 
expression compared to controls (p<0.05). B cells also showed increased TLR 7 and 9 mRNA 
expression compared to controls (p<0.05). Stimulation of TLR 3, 7, 8 and 9 in PBMCs leads 
to a significantly increased IFN-α protein and mRNA expression (p<0.05). Incubation of 
PBMCs with varying concentrations of apoptotic neutrophils demonstrated a dose-
response relationship as measured by IFN-α mRNA expression and TLR expression 
positively correlated with increasing apoptosis (p<0.05). MyD88 inhibition of PBMCs was 
found to effectively inhibit IFN-α mRNA expression in PBMCs incubated with TLR9 agonist 
and apoptotic neutrophils.          
Conclusions: This study has demonstrated increased TLR expression in JSLE PBMCs and B 
cells. We have shown TLR stimulation to result in IFN-α production and using this criteria 
have shown apoptotic neutrophils to be potent stimulators of TLRs and therefore a likely 
source of autoantigen in JSLE. The role of TLRs in this inflammatory response was 
demonstrated by a dose-response relationship to apoptotic neutrophil concentration and  
TLR expression being shown to positively correlate with apoptosis. MyD88 inhibition was 
shown to be an effective strategy in halting this inflammatory response to apoptotic 
neutrophils. 
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1 Introduction 
1.1 The Immune System 
The primary function of the immune system is the recognition and elimination of harmful 
pathogenic material. These actions are carried out to prevent or minimise the harmful 
effects of the presence of these substances. Pathogens have evolved many methods and 
modes of transmission and reproduction to which living organisms have had to evolve 
equally potent methods of protection to counteract their threat. This tug of war between 
mammals and the environment over millions of years has resulted in the creation of a 
multi-layered, interlocking defence mechanism incorporating both primitive and more 
recently evolved components. 
The immune response can be separated into two distinct, yet intricately interwoven 
systems. Primarily, the evolutionary ancient innate immune system is responsible for 
detecting pathogenic invasion, the initiation of a non-specific immune response and 
propagation of antigen-specific targeted immune response. This response is inborn and 
unchanging in its reaction to a particular pathogen. The adaptive immune system is then 
responsible for an antigen specific response in which an array of secretory antibodies and 
cell mediated methods are employed to destroy one specific pathogen. The employment of 
these two systems is a very effective method of defence against the environment and has 
maintained survival through evolution.    
1.1.1 The Immune Response 
Upon pathogenic invasion it is the responsibility of the innate immune system to identify 
foreign organisms amongst an array of body tissues. The innate immune system is capable 
of doing this through the detection of microbial markers, for example by-products of 
metabolism which are released into the body’s internal environment as a result of 
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respiration. These markers are unique to microorganisms but absent from their eukaryotic 
host and are therefore able to be recognised as non-self. The markers contain conserved 
molecular motifs which are used to distinguish between class of organism and are 
therefore termed pathogen-associated molecular patterns (PAMPs). Cells of the innate 
immune response, which primarily constitute phagocytes, bear receptors for specific 
PAMPs, termed pattern-recognition receptors (PRRs) [1-2]. Once stimulated, these cells 
engulf, internalize and destroy the pathogen. Specialised cells of the innate immune 
system, mainly dendritic cells (DCs) and macrophages, are capable of displaying the 
antigenic epitope of the ingested pathogen on their cell surface. These cells are termed 
antigen presenting cells (APCs) and their role is in linking the innate and adaptive immune 
response, allowing the production of a targeted antigen-specific immune response. T 
lymphocytes of the adaptive immune system express antigen specific receptors which are 
able to detect antigenic peptides only when bound to APCs. This is crucial as this highly 
discriminatory mechanism allows the recognition of specific pathogens and not just class of 
pathogen, as permitted by PAMP detection. Specific T helper cells stimulate B lymphocytes 
into clonal differentiation of plasma cells, which produce antigen-specific immunoglobulins 
capable of destroying the pathogenic invader. This process is complete and terminates 
once the pathogen, and therefore the antigenic stimulant has been eliminated. A 
proportion of these B lymphocytes persist in the body as memory B cells allowing a much 
quicker and effective immune response if the body should come into contact with that 
particular antigen (antigenic epitope) again. 
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1.1.2 Components of Innate Immunity 
Some form of innate immunity exists in all living organisms. The function of the innate 
immune system can be broken down into 2 mechanisms. 
1.1.2.1 Cell mediated innate defence 
The chief cell of the innate immune system is the phagocyte. This is a broad term describing 
any cell capable of ingesting and destroying pathogens [3]. In addition to its role in clearing 
pathogens they also have an important function in recognising cells undergoing apoptosis 
and are responsible for clearing this cellular debris [4]. The term phagocyte encompasses a 
variety of cells, however macrophages and neutrophils are considered to be the most 
important. 
Macrophages arise from myeloid stem cells in their immature form as monocytes where 
they migrate from the bloodstream to reside in different tissues in many forms. This cell 
has a particularly long life span and may reside in tissues for many years. Neutrophils are 
also descendants of myeloid stem cells and are the most numerous leukocyte in the body. 
They are attracted to sites of infection by pathogenic stimulation of resident macrophages 
in infected tissue, which produce soluble attractants called chemokines. They migrate 
rapidly to infected sites engulfing pathogens and exposing them to proteolytic enzymes 
which destroy the bacteria. They have a particularly short life span when active but release 
chemokines attracting other cells to the area, maintaining the immune response. 
Phagocytes owe their ability to respond to threats to a system of receptors. These include 
receptors for chemokines and cytokines, allowing the cell to navigate to the site of 
infection; complement, allowing the identification of candidates for phagocytosis (Section 
1.1.2.3); immunoglobulin, stimulating phagocytosis of antibody bound antigens and various 
PRRs (Section 1.1.1), which allow the body to determine the class of invading pathogen and 
mount an appropriate immune response.  
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1.1.2.2 Toll-like Receptors (PRRs) 
Toll-like receptors (TLR) are one class of PRR thought to be important in the innate immune 
response. They fall into the context of immunity at the very beginning of the innate 
immune response. The first TLR was identified as a maternal-effect gene that had a role in 
the signalling pathway controlling dorsoventral polarity in Drosophilia fruitfly embryos [5]. 
Analysis of the Toll gene revealed that in addition to its embryonic function it also encoded 
a transmembrane protein with a similar cytoplasmic domain to the mammalian interleukin-
1 receptor (IL-1R) [6]. This suggested that drosophilia toll was not only instrumental in 
embryonic development but also had a function in the immune response of adult fruit flies. 
A study by Lemaitre et al confirmed this hypothesis by demonstrating increased fungal 
susceptibility in toll gene deficient flies [7]. However drosophilia toll are incapable of 
directly identifying pathogens and therefore do not act as PRRs. Alternatively a pro-enzyme 
is cleaved immediately upon infection into an active form which goes on to stimulate the 
Toll pathway and induce an immune response [8]. TLR4 was the first TLR to be identified in 
humans [9]. 
In humans, TLRs comprise a family of 10 type 1 glycoprotein receptors characterised by an 
extracellular leucine-rich repeat domain and an intracellular Toll/IL-1R (TIR) domain [5, 9-
11]. TLRs detect PAMPs from a diverse range of pathogens including viruses, bacteria, fungi 
and protozoa (Figure 1) [12]. The chief function of TLRs is the induction of inflammation 
and establishment of an adaptive immune response.  Once stimulated they initiate a 
signalling cascade which results in the production of cytokines activating the surrounding 
cells resulting in the secretion of chemokines. Recruited neutrophils and macrophages are 
attracted to the site of inflammation where they ingest the pathogens through 
internalisation and activate the adaptive immune response [13].  
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TLRs are able to be distinguished not only by their pathogenic ligand but also by their 
cellular location. TLRs 1, 2, 4, 5, 6 are situated on the cell surface whereas TLRs 3, 7, 8 and 9 
have an intracellular location (Figure 1) [14]. 
Figure 1: TLR cellular location and natural ligands [15] 
 
 
 
 
 
 
 
 
 
 
The intracellular location of TLRs 3, 7, 8 and 9 is thought to be due to the origin of their 
natural ligands. As nucleic acid receptors they are susceptible to activation by self nucleic 
acids and therefore capable of detecting self-antigen. It has been shown that if TLR9 is 
manipulated to be expressed on the plasma membrane it can be stimulated by self DNA 
[16]. Endosomal sequestration of these TLRs is thought to protect them from gaining 
contact with endogenous nucleic acids, while still allowing detection of exogenous nucleic 
acids [13]. 
1.1.2.3 Soluble Mediators of the Innate Defence 
The innate immune system is reliant upon a host of soluble proteins to initiate a rapid 
response. Type 1 interferons (IFNs) comprise a family of associated cytokines essential in 
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the innate immune response. Cytokines are soluble messenger molecules secreted by cells 
of the immune system [3]. This group of cytokines is named after their ability to interfere 
(interfer-) with viral replication (-on), practical applications of this can be seen in the use of 
recombinant IFN-α for treating viral hepatitis [17]. Serum levels are increased hours after 
infection inhibiting further viral replication and stimulating innate immune cells to destroy 
infected cells [18]. IFNs also enhance antigen presentation, ensuring a more rapid adaptive 
immune response [19]. There are many cytokines important to the function of the immune 
system but IL-1, IL-6 and Tissue Necrosing Factor (TNF) are of particular importance due to 
their role in linking all facets of the immune system to produce one overall effective and co-
ordinated immune response [18].  
Another very important part of the innate immune response is the complement system of 
proteins which comprises 9 major components C1-9 and some smaller fragments. This 
system is directly and indirectly responsible for inducing cell death. Indirectly it causes the 
release of inflammatory cytokines and chemokines attracting cells of the immune system to 
target areas and the binding of opsonins to target cells allows identification off candidates 
for phagocytosis [3]. Directly, they are capable of disrupting the cell structure through a 
process of membrane lysis destroying cell integrity allowing leakage of contents resulting in 
cell death [3].   
1.1.3 Bridging Innate and Adaptive immunity 
An effective immune response relies on the ability of the innate system to stimulate the 
adaptive immune system into a pathogen specific response. The Major Histocompatibility 
Complex (MHC) comprises a group of antigen-receptor molecules. Class I MHC molecules 
are present on virtually all cells and class II MHC molecules are present mainly on B cells, 
macrophages and dendritic cells. The function of this group is to identify and present 
antigen to cells of the adaptive immune system, promoting an antigen specific response. 
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Once cells of the innate immune system are stimulated they can produce a range of 
cytokines which induce proliferation of APCs, promoting a more efficient response, and 
cells involved in cell mediated and humoral immunity. 
1.1.4 Adaptive Immunity 
Cells of the adaptive immune system require activation by the innate immune system 
before they can begin to exert their effects. Cell mediated immunity is the process by which 
CD8+ cytotoxic T cells (Tc cells) migrate into peripheral tissues, physically and chemically 
attacking antigens [20]. However these cells must first be primed for activity by APCs 
before they can exert their effects. Once primed Tc cells will destroy any tissue bearing the 
antigenic epitope for which they have been primed. Each B cell carries its own unique 
antibody. Once this antibody comes into contact with its complementary antigen the B cell 
undergoes sensitization, a process by which the cell prepares for activation [21]. Once 
sensitized the B cell will not become active until stimulated by an activated CD4+ T helper 
cell (TH cell) [21]. These cells also carry their own unique receptor called the T cell receptor 
(TCR) and undergo activation when presented with an antigen from an APC that’s epitope 
is specific for their TCR [17]. Once activated they promote B cell activation through the 
stimulation of the B cell receptor (BCR).  Some antigens also have the ability to directly 
stimulate B cell activation in the absence of TH cell assistance, these are termed T cell 
independent antigens [3]. Once activated, B cells undergo clonal expansion producing 
daughter cells which differentiate into plasma cells, capable of producing large volumes of 
soluble antibody, and memory cells, which persist after first exposure and confer long-
lasting immunity (Figure 2) [20].      
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Figure 2: Overview of the Adaptive Immune Response 
 
 
 
 
 
 
 
 
 
 
Antigen presenting cells (APC) detect antigen through pattern recognition receptors such as TLRs. B cells 
detect antigen and undergo sensitization. CD4
+ 
cells bind to APCs upon recognition of antigen and stimulate B 
cell clonal proliferation and produce antibody against target antigen. CD8
+
 cells become activated once they 
detect antigen on APC. They migrate toward sites of infection and initiate an immune response upon contact 
with the antigen they have been activated towards (Adapted from Immunology [3]). 
1.1.5 Apoptosis 
The process of apoptosis lies in the biochemical and morphologic events that occur to 
induce programmed cell death [22]. There are two major pathways involved (Figure 3). The 
extrinsic pathway is induced through death ligand/receptor interactions, such as FasL/FasR 
and TRAIL/Death Receptor (DR) 4/5 [23]. This stimulates the recruitment of an adapter 
protein, Fas Associated Death Domain (FADD), which cleaves pro-caspase 8 to its active 
form, caspase 8 [23]. The intrinsic pathway involves the release of cytochrome c from 
mitochondria leading to the activation of caspase 9. Both caspase 8 and 9 have the ability 
to cleave pro-caspase 3 to its active form, caspase 3, initiating the death cascade [23-24]. 
This process is integral in maintaining normal homeostasis and regulating immune 
autoreactivity through the deletion of autoreactive and immunologically redundant cells 
[4]. Apoptotic cells are recognised and cleared by phagocytes without inducing an 
This text box is where the unabridged thesis included the following 
third party copyrighted material: 
Adaptive Immune Response 
Male D, B.J., Roth DB, Roitt I, Immunology. 2007: Elsevier 
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inflammatory reaction [4]. Necrosis is unprogrammed cell death usually the result of tissue 
insult and results in an inflammatory response [25]. 
Figure 3: Intrinsic and Extrinsic Apoptotic Pathway 
 
 
 
 
 
 
 
 
This figure is adapted from LeBlanc and Ashkenazi 2003. Death ligands/receptor interactions, for 
example TRAIL, stimulate the activation of caspase 8 through the extrinsic pathway. Mitochondria 
produce cytochrome c (cyt c) to activate caspase 9 through the intrinsic pathway. Caspases 8 & 9 
activate caspase 3 initiating apoptosis [26]. 
 
1.2 Autoimmunity 
Autoimmunity can be defined as an adaptive immune response with specificity for self-
antigens [27]. This process involves the production of autoantibodies against normal cell 
constituents, which in this scenario are looked upon as autoantigens. A certain level of 
autoantibody production is seen in healthy individuals and is considered normal. This is 
probably due to the process of random Ig gene recombination by which antigen receptor 
genes are randomly re-arranged with the intention of creating a diverse set of receptors 
capable of identifying all the antigens present in our environment [17]. A negative aspect of 
this process is the inevitability of the creation of receptors specific for host antigens. If the 
cell should come into contact with this antigen an autoimmune response may be mounted. 
However an extensive network of self-tolerance checkpoints ensures that significant 
numbers of these auto-reactive cells do not enter the active cell population. Central 
This text box is where the unabridged thesis included the following 
third party copyrighted material: 
Apo2L/TRAIL DISC assembly 
 
LeBlanc, H.N. and A. Ashkenazi, Apo2L/TRAIL and its death and  
decoy receptors. Cell Death Differ, 2003. 10(1): p. 66-75. 
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tolerance occurs in the thymus.  Any T cell that binds to autoantigens present in the thymus 
will be deleted by negative selection. However not all autoantigens are present in the 
thymus and consequently some cells escape negative selection. Peripheral tolerance 
involves three mechanisms: sequestration of self-antigen so that autoreactive T cells 
cannot come into contact with it; immunologic privilege by where the self-antigen is 
protected from contact by physical or chemical means and anergy or apoptosis through 
deficiency in required co-stimulatory molecules [28]. If any of these mechanisms are 
ineffective then self-tolerance may be lost. For example if dsDNA is expressed in low levels 
in the thymus a cell may escape central tolerance, in addition to this if there is a deficiency 
in complement then cell debris, for example dsDNA, may be present in the circulation 
inducing an immune response resulting in the production of anti-dsDNA autoantibodies. 
There are many examples of autoimmune diseases in which the body mounts a response 
against itself, and it is no surprise that due to the complexity of their nature they are one of 
the more challenging groups of conditions to unravel their immunopathogenesis. 
1.2.1 Apoptosis in Autoimmunity 
Defects in apoptosis are implicated in the pathogenesis of many significant diseases, 
including cancer, heart disease and many autoimmune diseases [25]. One example of 
dysregulated apoptosis leading to autoimmunity is the lymphoproliferative disorders were 
a failure of apoptosis leads to the unregulated proliferation of lymphocytes. For example in 
autoimmune lymphoproliferative syndrome, inherited defects in B cell apoptotic pathways, 
involving Fas, Fas ligand and the caspases, result in abnormalities in B cell apoptosis leading 
to uncontrolled clonal expansion of B cell populations which have the potential to develop 
into B cell lymphoma.  Conversely it has also been demonstrated that increased apoptosis 
may also lead to the development of autoimmune disease through increased exposure of 
self-antigen [22, 25]. This is thought to occur due to apoptosis leading to the breakdown of 
cell membranes exposing self-antigen, providing the opportunity for autoimmunity.  
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1.2.2 TLRs in Autoimmunity 
For years the induction of autoimmunity was thought to be solely dependent on the 
dysfunction of T and B cells. Now as we begin to better understand the functions and 
mechanisms of the innate immune system it has come to be accepted that it may be 
implicated in the triggering of autoimmunity [29]. Understandably this has led to a wave of 
research into the roles of TLRs in autoimmunity, in particular 3, 7, 8 and 9. The interest in 
these arises from the presence of nucleic acid derived autoantibodies in many autoimmune 
conditions, indicating that humans may be susceptible to detecting host DNA. The fact that 
these TLRs are capable of detecting nucleic acids has directed research in their direction. 
Mechanisms that prevent the detection of host nucleic acids are thought to be due to their 
endosomal localisation and subtle differences in the fundamental structure of exogenous 
and endogenous nucleic acids, allowing differentiation between the two [16, 30-31]. 
However, abnormalities in their regulatory role, or increased production and therefore 
potential exposure to self-antigen may result in them being activated in response to 
endogenous nucleic acids. Recent research has implicated TLRs in the pathogenesis of 
human SLE, rheumatoid arthritis (RA), diabetes and antiphospholipid syndrome [32-35]. 
This theory is further supported by the fact that TLR inhibitors have been being used in the 
treatment of autoimmune conditions for years. Hydroxychloroquine, initially developed as 
an anti-malarial drug is also employed in rheumatoid arthritis (RA), juvenile idiopathic 
arthritis (JIA), SLE and JSLE [36-37]. It is now known that the drug acts a potent inhibitor of 
TLRs 3, 7, 8 and 9 [38]. The fact that clinical and serological improvement can be seen with 
the use of this drug supports the potential role of TLRs in the development of 
autoimmunity. 
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1.3 JSLE 
1.3.1 Background 
Juvenile-onset Systemic Lupus Erythematosus (JSLE) is the childhood form of Systemic 
Lupus Erythematosus (SLE). It is a rare condition with an incidence of less than 1/100,000 
[39]. Onset occurs prior to the age of 18, typically between 12-16 years although children 
can be diagnosed at a much earlier age, and accounts for up to 20% of all cases of SLE [40-
42]. Gender predilection towards females is more balanced than in adult disease, with 
female:male ratios being approximately 5:1 and 8:1 respectively for pre- and post-pubertal 
young people [43]. It is a chronic, debilitating, multi-system autoimmune condition which 
has a more severe disease-onset and presentation and more aggressive clinical course than 
the adult form [44-48]. JSLE can present with severe life threatening disease, but often can 
be characterised by non-specific symptoms such as fatigue, mouth ulcers, arthralgia / 
myalgia and low mood, which in a teenage population may have many varied aetiologies. 
Such vague presentation, combined with low awareness among clinicians, health care 
professionals and the general population that lupus can occur in children, mean that it is 
often not recognised early on, leading to significant delays between initial presentation and 
diagnosis [49].  
 
1.3.2 Clinical Characteristics 
The complexity of this disease is reflected in the wide diversity of clinical and 
immunological manifestations that characterise lupus as well as the criteria upon which 
diagnosis is based. There are no validated diagnostic criteria for either juvenile- or adult-
onset SLE, but diagnosis is currently based upon the revised American College of 
Rheumatology classification criteria for SLE. These consist of 11 criteria (Table 1) of which 
four have to be met, cumulatively, before a diagnosis is formally made [50-51]. Although 
these criteria were intended for adults, their use has been adopted and subsequently 
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validated in the juvenile population [52]. However, differences in disease spectrum 
between adult and paediatric-onset disease means that young people are often deemed by 
their clinician to have or be developing lupus, without strictly meeting these criteria.  
Table 1: Diagnostic criteria for SLE (Adapted from Tucker et al [9]) 
Revised ACR 1997 criteria (ref) 
Malar Rash 
Discoid Rash 
Photosensitivity 
Oral or nasal ulcerations 
Nonerosive arthritis 
Nephritis 
              Proteinuria >0.5g/day 
              Cellular casts 
Encephalopathy 
          Seizures 
              Psychosis 
Pleuritis or pericarditis 
Cytopaenia 
Positive immunoserology 
              Antibodies to dsDNA &/or Sm nuclear antigen 
              Positive findings of antiphospholipid antibodies 
- Anti-cardiolipin antibodies 
- Lupus anti-coagulant 
Positive antinuclear antibody test  
 
Although there are strong similarities in the disease spectrum between JSLE and the adult 
form, there are clear differences in the clinical presentation. It has been found that 
constitutional symptoms, arthritis, visceromegaly, nephritis, lymphadenopathy, 
neurological and haematological abnormalities are far more prevalent in the juvenile 
population [53-54]. Although constitutional symptoms, defined as fever, fatigue and weight 
loss, are not part of the diagnostic criteria they can have a profound influence on clinical 
wellbeing and are thought to be the result of the underlying disease process in JSLE. In 
addition to the increased frequency of these manifestations in JSLE, they are also found to 
be more aggressive and poor prognostic markers of SLE in general [53]. 
 
≥4 of the diagnostic criteria have to be met cumulatively for diagnosis 
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1.3.3 Immunopathology 
The underlying immunopathology in JSLE is characterised by an overwhelming dysfunction 
of the normal immune response. The complex pathology of this condition has recently 
begun to unravel with advances in our understanding of the normal immune response and 
observations of abnormal cell functions in JSLE. To date, T cell autoreactivity, B cell 
hyperactivity, dendritic cell dysfunction and altered complement and cytokine profiles have 
all been implicated in the disease process [55-56]. The serological hallmark of JSLE is the 
production of auto-antibodies, directed against nuclear auto-antigens which are thought to 
arise from the immune dysfunction. The most characteristic of these anti-nuclear 
antibodies (ANAs) is anti-dsDNA directed against self-dsDNA. The full significance of these 
auto-antibodies has yet to be completely determined but it is hypothesised that they lead 
to the formation of immune complexes (IC) with their auto-antigens and are spontaneously 
deposited in body tissues, leading to an inflammatory response, cytokine production, tissue 
damage and eventual necrosis. This is supported by the positive correlation between the 
presence of anti-dsDNA titres and lupus nephritis [57].  
1.3.3.1 Genetic Factors 
It is universally accepted that genetic predisposition is a key factor in the development of 
SLE. The children of parents with SLE are 20 times more likely to develop the condition than 
the general population [58]. Twin studies propose a 24% concordance rate in monozygous 
twins, reduced to 2% in heterozygous twins [59]. As well as providing evidence for a genetic 
link of inheritance these studies also highlight the importance of environmental factors on 
the development of JSLE. In two people with identical genes the only other factor that can 
influence their development is the environment in which they are exposed to. Therefore 
the condition is likely to develop where there is a genetic predisposition followed by an 
event or events that initiate and then maintain disease progression through an 
accumulation of risk factors which all must be present at the same time or exposed to over 
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time. The likelihood of developing JSLE is also increased with a positive family in first 
degree relatives, the risk increasing with the number of affected family members [60] .  
Interestingly, the strongest risk factor for developing SLE lies in the homozygous deficiency 
of any one of the early components of the classical complement pathway, important in the 
clearance of apoptotic cell debris [61-64]. Prevalence and severity of the condition can be 
ranked dependent upon the missing protein. There is an increased association and severity 
of condition with deletion of C1-complex or C4 molecules and a decreased prevalence and 
severity with C2 deletion, however a third of these patients will still go on to develop SLE   
[61-63, 65]. This is extremely interesting in the context of recent research investigating the 
role of apoptosis and defective cell clearance in the pathogenesis of adult and juvenile-
onset SLE [25, 44].  
Although important, this genetic deficiency is by no means the full story, with associations 
between variations in HLA type [65], cytokine associated genes [19], Fcγ receptor genes 
[65], mannose binding lectin [66] and cell apoptosis controlling genes being shown to be 
strongly associated with disease development in humans. This array of “susceptibility gene” 
alterations of different components of the immune response is an insight into the 
complexity of the immunopathology of this heterogeneous disease and allows a glimpse of 
the scale of the task of unravelling just this aspect of disease pathogenesis.  
Homozygous TREX1 mutation is most commonly known as the cause of Aicardi-Goutières 
Syndrome, whilst heterozygous mutations result in familial chilblain lupus [67-68]; of note 
up to 2% of adult SLE patients have mutations of this gene [69]. This association is 
important as deficiencies in this gene lead to defects in nucleic acid metabolism leading to 
high levels of IFN-α, a cytokine noted to be important in the pathogenesis of SLE [70].  
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Considering the highly heterogenic nature of this condition it is highly unlikely that there is 
one specific gene profile that could be used to identify those that have or are likely to 
develop SLE. However, investigating the genetic factors important in the development of 
the severe phenotype of the childhood form of SLE and their functional downstream 
consequences will provide important insights into the aetiology of this archetypal 
autoimmune disease. It is probable that there are a number of genetic permutations or 
susceptibility genes that result in the manifestation of this disease and it is these 
permutations that may explain discrepancies between disease manifestation in individual 
patients.  
1.3.3.2 Cytokines 
Recent advances in biotechnology have led to a renaissance into the study of the 
underlying mechanisms which may cause SLE. A result of this has been the discovery of a 
whole host of abnormal variations in cytokine-associated genes leading to a renewed 
interest into the role that cytokines have to play in SLE. It has been hypothesised that 
cytokines are not only important in the maintenance of disease but also may be critical in 
the initiation of autoimmunity [71]. 
Increased serum levels of cytokines have been demonstrated on numerous occasions in 
SLE. The most important set of cytokines in SLE are thought to be the IFN’s. The IFN family 
consist of 13 IFN-α subtypes, IFN-β and IFN-ω [72].  High serum IFN-α levels are a common 
feature of SLE and have been shown to correlate well with disease activity and severity [73] 
and high serum levels are a heritable risk factor for disease [74]. Indeed IFN pathway 
activation has been shown to be associated with more severe disease [75]. This increased 
protein level of IFN-α translates to a genetic ‘IFN signature’ where genes involved in the 
IFN-α pathway are up-regulated [76]. Interestingly, incubating cells with JSLE serum 
increases IFN-α expression, identifying a serum factor for this mechanism [24]. The main 
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source of IFN-α is thought to be through plasmacytoid dendritic cell (pDCs) stimulation by 
immune complexes containing SLE autoantibodies [77]. These immune complexes are 
thought to be internalised upon binding with pDCs at which point they can activate 
intracellular TLRs [15]. This  increased IFN-α level results in the unremitting differentiation 
and activation of pDCs which present antigens from apoptotic cells  resulting in the 
activation of autoreactive T cells and in the loss of peripheral self-tolerance (Figure 4) [19]. 
IFN-α also has the capacity to directly stimulate B cells enhancing antibody and 
autoantibody production [19]. Its role in the aetiopathogenesis of lupus is further indicated 
by induction of a lupus-like syndrome upon commencement of recombinant IFN-α therapy 
and abation of these symptoms following withdrawal [78-79]. These data indicate a 
population of patients with a genetic background leading to susceptibility for lupus, and are 
further supported by the identification of SLE susceptibility genes linked to IFN cytokine 
production [80].  
Although IFN-α is the major cytokine commonly attributed to the pathogenesis of JSLE, 
patients also express other abnormal cytokine profiles. Levels of B-Lymphocyte stimulator 
(BLyS or BAFF), IL-6, IL-10 and IL-12 have also been found to be increased in SLE and to 
correlate with disease activity, while IL-2 has been reported to be low [18, 81-86]. IL-6 is 
responsible for the maturation of IFN-α induced, non-immunoglobulin (Ig) secreting 
plasmablasts into Ig-secreting plasma cells and therefore it’s up-regulation in SLE patients 
with high serum IFN-α is of note [87]. BAFF induces the proliferation of B cells and has been 
implicated in the expansion of autoreactive B cells. Serum levels of this cytokine have been 
shown to be increased in SLE [88]. This observation has led to clinical trials of anti-BAFF 
therapy which have shown therapeutic benefit [89].    
Although there are cytokines that may have a profound influence on the evolution and 
maintenance of disease, it is unlikely that targeting just one cytokine will induce disease 
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remission, as has been successfully implemented in inflammatory arthritis [90]. Cytokines 
rely on such a delicate intricate system of positive and negative feedback loops, and SLE is a 
disease of such complexity, that it is likely that only by targeting a host of cytokines, their 
receptors or the immune cells producing them, will result in a clinically significant remission 
of disease. Whether this clinical benefit comes with an acceptable safety profile is another 
important question. It therefore underlines the importance of determining the early 
triggers of subsequent downstream dysregulation of the immune pathway, and the 
interaction between the innate and adaptive immune system. 
Figure 4: The role of IFN-α in Lupus [91-92] 
 
  
The central role of type I IFN in SLE pathogenesis. Several genetic alterations predispose to SLE. 
For example, genes involved in IFN production, B cell tolerance and clearance of cell debris. SLE 
flares are associated with environmental factors such as viral infections triggering the unabated 
production of IFNs. Type I IFN induces the generation of mature DCs, which expand autoreactive T 
lymphocytes that have escaped central tolerance. Autoreactive CD8
+
 T cells damage tissues 
releasing large numbers of nucleosomes, captured by mature DCs, amplifying the autoreactive 
process. IL-6 and IFN promote the proliferation of autoreactive plasma cells. Immune complexes 
activate B cells through the engagement of BCR and TLRs inducing pDC IFN-α production. Red 
arrows indicate direct effects of type I IFN on DCs and B cells. Black arrows indicate indirect 
effects, either as a result of IFN-induced DC activation or through immune complex generation. 
This text box is where the unabridged thesis included the following 
third party copyrighted material: 
The role of IFN-α in Lupus 
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1.3.3.3 Dendritic Cells 
There has been much interest in the role of DCs in SLE. As with many cells of the immune 
system in JSLE, blood levels have been found to be significantly decreased [93-94]. 
However biopsies have revealed their presence in cutaneous lupus erythematosus lesions 
[95]. IFN-α can induce the differentiation of immature DCs into active DCs. In a healthy 
model this would mean that when the body required to activate DCs it would produce 
increased levels of IFN-α, which would be down-regulated once the desired response had 
been achieved. This is what is thought to maintain the peripheral tolerance to self-antigens 
in healthy subjects. However in JSLE there are high levels of IFN-α which may lead to the 
persistent activation of DCs [24]. Interestingly it is thought that plasmacytoid DCs (pDCs) 
are the main source of IFN-α in SLE [77]. This supports the hypothesis that pDCs may 
actively contribute to their own auto-reactivity. With persistently high levels of IFN-α, 
immature pDCs may be being stimulated to present autoantigen leading to the 
development of autoreactive T cells and the initiation of autoimmunity. As the pDCs are 
being stimulated they will simultaneously produce IFN-a thereby forming a feedback loop 
of autoantigen presentation and stimulation of autoreactive cells promoting the 
persistence of autoimmunity [44]. 
1.3.3.4 B cells and auto-antibody production 
The focus of interest in the role of B cells in the disease process in JSLE is clear. As the only 
cells capable of producing antibodies they are implicated in the disease pathophysiology; 
whether their role is secondary, being driven to produce auto-reactive antibodies by up-
stream signals, or whether they play a more primary role poses a more challenging 
question. Lymphopenia is a common problem in JSLE, however it has been found that the B 
cells that are present display abnormal phenotypes suggestive of activation [92]. The 
significance of the role of B cells in JSLE pathology has been heavily implied by case reports 
in SLE patients whose symptoms have abated with concomitant development of B cell 
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dysfunction [92]. Interestingly murine models have indicated that the role of the B cell in 
JSLE pathogenesis is not only in auto-antibody production but may also lie in their ability to 
stimulate other cells of the immune system including T cells and DCs. Lupus mice with B 
cells incapable of producing antibodies maintain symptoms of SLE, many of which are lost 
upon B cell depletion [96]. One theory is that as B cells are capable of acting as APCs; an 
autoreactive B cell could lead to the activation of an autoreactive TH cell which in turn could 
stimulate the proliferation of autoantibody producing plasma cells [92]. This evidence has 
led to the production of B cell targeted therapies which have been shown to have 
therapeutic advantages in a range of autoimmune conditions including JSLE [97-101].  
Studies into B cell function have found significant alterations in B cell compartments and 
phenotype [92]. Despite low levels of naïve and memory B cells there is a disproportional 
increase in antibody producing CD38+ plasma cells. Further to this, in health where there is 
a waxing and waning of plasma cell populations in response to pathogenic infection it has 
been found that there are persistently raised levels of this cell in SLE, indicating that 
antibody production is being driven by a factor other than host infection [77].  
As has previously been noted, raised levels of IFNs have the ability to induce B cell 
proliferation and are likely to be involved in the proliferation of autoreactive B cells [87]. 
Interestingly it has also been found that T and B cells increasingly express CD40 ligand 
(CD40L) in SLE. This protein is required for the activation of many antigen presenting cells 
including B cells and DCs and in vivo is usually provided by T lymphocytes [102]. This finding 
is further consolidated by the eradication of plasma cell types in adult SLE with the addition 
of anti-CD40L mAb [102]. These two processes may work independently or as part of a 
bigger mechanism in contributing to JSLE pathology.  
In health it has been shown that a significant proportion of immature B cells express mRNA 
for auto-antibodies, however these are removed from the mature B cell population [103]. 
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The VH4-34 gene has been found to encode for a variety of auto-antibodies, including anti-
dsDNA antibodies [104]. Interestingly SLE serum contains increased levels of 9G4, an 
idiotype encoded by the VH4-34 gene, and furthermore these titres appear to correlate 
with disease activity [105]. These data support the possibility that in SLE there is a defect in 
the mechanism that usually filters the auto-reactive B cells from the general B cell pool and 
this in turn is permitting the maturation of these auto-reactive immature B cells.  
Prospective studies have shown that auto-antibody production may precede diagnosis by 
many years [106]. The onset of overt clinical disease has been shown to be associated with 
the presence auto-antibodies to dsDNA, Smith antigen and nuclear ribonucleoproteins 
which, coincidentally, are the last of the auto-antibodies to appear in SLE [106]. This may 
have significant pathological consequences as immune complexes containing DNA are 
capable of stimulating auto-antibody secretion [107]. Furthermore anti-dsDNA and anti-
nRNPs antibodies can trigger the secretion of IFN-α [108-109] from pDCs, which, as 
previously mentioned, can stimulate the development of mature plasma cells, creating a 
self-perpetuating cycle of inflammatory cytokine secretion and auto-antibody production 
[87].  
1.3.3.5 T Cells 
As with B cells, T cells of SLE patients have been found to have a lower threshold for 
antigenic response than healthy T cells [110]. These cells also seem to be able to resist 
deactivation and apoptosis through dampening down of the extrinsic apoptotic pathway 
[111]. Firstly the fact that these hyper-reactive T cells are present in the body is an 
indication of an irregular immune complexion; secondly the fact that these cells can persist 
beyond the normal life-span of T-lymphocytes indicates a set up primed for immune 
dysfunction, such as that seen in JSLE. The persistence of these cells may indeed contribute 
22 
 
the disease process in JSLE. Two T cell subtypes have received particular attention in 
regards to SLE in recent years. 
Type 17 helper (TH17) cells are CD4
+ cells that have undergone antigen priming resulting in 
phenotypic differentiation into a cell capable of inducing intense inflammatory responses 
[112]. They owe this ability to the production of several potent cytokines, in particular IL-
17, which has an important role in neutrophil recruitment and also has the ability to 
stimulate antibody production [112]. Levels of this cell type and this cytokine have both 
been found to be increased in SLE suggesting they may have a function in the pathogenesis 
of SLE [113]. 
Regulatory T cells (TREG) persistently express CD4
+ cells and are important in maintaining 
immunological tolerance [112]. Their significance is implied by the observation that 
absence of these cells leads to the development of fatal autoimmunity [112]. It has been 
found that these cells are depleted in SLE and to compound this the cells present function 
poorly [114-115]. The cytokine profile in SLE is thought to contribute to this abnormality.  
IL-2 reported to be low in SLE is vital for the maturation of this cell type and IL-6, capable of 
inhibiting these cells, is present in high levels [86, 116]. Dysfunction of this cell type could 
be a factor in and contribute to T cell dysregulation and auto-antibody production in JSLE 
1.3.3.6 Apoptosis 
The premise that apoptosis is essential in maintaining immune integrity allows for the 
suggestion that defects in this mechanism may lead to immune irregularities. This is 
certainly thought to be the case in SLE [117]. It is thought that failure of the body to clear 
apoptotic cells is allowing the exposure of antigenic cellular components leading to the 
abnormal presentation of host derived auto-antigens [44]. This is based on evidence 
showing increased rates of apoptosis in combination with defective clearance of apoptotic 
material resulting in increased levels of circulating apoptotic cells in SLE [4, 118-120].  
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Our laboratories have explored the specific role of apoptosis in JSLE and have recently 
demonstrated an increased rate of neutrophil apoptosis in JSLE when compared to control 
[24]. Furthermore this increased rate was shown to be positively correlated with disease 
activity, as measured by the British Isles Lupus Assessment Group (BILAG) index, and anti-
dsDNA titres [24, 121]. The cause of this increased apoptosis is thought to be due to the 
imbalance of the normal relationship between pro-apoptotic and anti-apoptotic factors in 
JSLE serum. Levels of granulocyte macrophage-colony stimulating factor (GM-CSF), cellular 
inhibitor of apoptosis (cIAP) 1, cIAP2 and X-linked inhibitor of apoptosis, all thought to be 
anti-apoptotic factors, are reduced in JSLE, whereas levels of TRAIL, FasL, Caspase 3, 
TRAILR-1, Fas and FADD, pro-apoptotic factors are increased. This hostile internal 
environment promoting neutrophil apoptosis is evident in clinical practice by marked 
neutropenia in JSLE patients. How this may be contributing to the disease process is 
unclear but the correlation between the level of neutrophil apoptosis, anti-dsDNA and 
disease activity implies that it may be a major contributor to the disease process. It is 
unclear whether the levels of apoptosis are a driving cause of pathology or a consequence. 
One hypothesis is that when these neutrophils undergo apoptosis, nuclear auto-antigens 
are being allowed to migrate to blebs on the cell surface and breach the cell membrane 
[122]. This allows the body to generate an immune response against these self-antigens 
ultimately resulting in anti-nuclear antibody production. Deficiencies in cell clearance, for 
example genetic deficiencies in complement components, may be compounding this 
problem[36].  
1.3.3.7 TLRs in SLE  
The last 10 years has seen much interest in the role of TLRs in autoimmune disease. The 
recent evidence base indicates that TLRs also have a role to play in the development of SLE. 
Although up-regulation of other intra-cellular TLRs has been detected, the main focus has 
been placed upon TLR 9, attributable to its ability to recognise self-dsDNA and the 
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invariable presence of anti-dsDNA in SLE. A recent case report has provoked further 
interest [123]. A lady with a 20 year history of severe SLE experienced spontaneous 
remission of clinical symptoms as well as eradication of anti-dsDNA titers with the 
simultaneous development of common variable immunodeficiency (CVID). Examination of 
the patients B cells revealed an acquired defect in the signalling pathway of TLRs 7 and 9. 
Although a unique case it highlights the possibility of the significance of TLRs in SLE. A 
number of studies have found increased expression of TLR 9 in SLE [32-33, 124-126]. 
Interestingly this increased expression has been found to be positively correlated with 
disease activity (SLEDAI), anti-dsDNA titers and cytokine production in the form of IFN-α 
and IL-10 [32, 125]. These findings are highly suggestive of a pivotal role for TLRs in the 
pathogenesis of SLE. However genetic studies analysing the TLR gene in patients with SLE 
have shown no link predisposing genetic variations of the TLR gene to increased 
susceptibility to SLE [127-128]. In view of the key role TLRs have in linking the innate and 
adaptive immune system and the downstream consequences of this, it is therefore of great 
importance to investigate further the role of TLRs in the pathogenesis of lupus. 
1.3.4 Management 
Management of any severe, chronic disease is a challenging and complex task [36]. In JSLE 
this importance is amplified by the fact that having significant disease during a time of such 
crucial physical, educational and psychological development can have serious long-term 
implications on future health and well-being. The degree of challenge is further intensified 
by concordance issues particularly during adolescence at a time when body image is at its 
most fragile. The negative effects of the disease and treatment alike can lead to reduced 
compliance which in turn allows disease progression requiring further treatment, which 
may lead to increased frequency or intensity of the negative effects they were hoping to 
initially avoid. Concerns regarding long-term treatment effects can also lead to 
concordance issues with not only patients but parents alike. 
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The evidence base for treating JSLE is significant only in its absence. Despite a large body of 
studies assessing treatment of adult-onset SLE, there have been no clinical trials assessing 
the use of therapeutic medications in juvenile-onset. This is surprising and unfortunate 
given that JSLE has been found to be more severe than adult SLE and the emphasis on 
effective disease control should therefore be greater given its consequences on short and 
long-term morbidity [53]. Therefore, as with other areas of this condition, treatment is 
largely based upon observations from adult-onset SLE and applied without sufficient 
exploration of efficacy. Although increased recognition and new treatments are largely to 
account for increased survival in JSLE, much more work is required in this field if further 
advancements are to take place. 
Predictably in JSLE the mainstay of treatment is targeted towards a dampening down of the 
immune response. Mild disease can be sufficiently treated with non-steroidal anti-
inflammatory drugs and hydroxychloroquine [36-37]. Corticosteroids are almost universally 
employed and are very effective in regaining control of the disease. Due to the increased 
prevalence of aggressive disease in JSLE there is often a sustained demand for high dose 
steroids, which although providing amelioration of the disease bring their own health 
consequences. Problems such as weight gain, failure to thrive, delayed puberty and striae 
are just a few of the symptoms that can most distress patients provoking disconcordance. 
However there are more worrying consequences of prolonged steroid exposure such as 
osteoporosis and premature atherosclerosis which will have more serious implications on 
long-term morbidity and mortality. This has led to the dual use of immunosuppressive 
agents such as azathioprine to reduce the steroid burden. Mycophenolate mofetil is a drug 
initially developed for use as an immunosuppressant in organ transplantation. However its 
use in adults with lupus nephritis has shown it to be as effective but less toxic than 
cyclophosphamide when used in addition to steroids [129]. Rituximab is a monoclonal 
antibody directed at human CD20, present at all stages of B cell development excluding the 
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earliest and latest stages [130]. Its potential treatment effect in JSLE could be significant, 
considering the role of hyperactive B cells in JSLE. It has been shown to reduce disease 
activity, decrease anti-dsDNA titres and improve renal function in JSLE [131]. However the 
safety of the drug has been put into question, delaying its widespread employment [132]. 
Pulsed intravenous cyclophosphamide is considered the gold standard treatment for the 
most severe cases of JSLE [43]. However, as with steroids there are significant adverse 
short and long-term effects which may hinder its application. The advent of biologic 
therapies offers new and important therapeutic avenues for the treatment of JSLE. Current 
trials of some of these agents in adult-onset SLE demonstrate their potential therapeutic 
benefits but also the challenges of clinical trials in lupus, and especially JSLE [18, 112, 133]. 
1.3.5 Prognosis 
Advances in the management of JSLE have significantly decreased levels of mortality, but 
consequentially has led to a substantial increase in the recognition of risks for long-term 
morbidity [134]. This is in the main part due to extended disease sequelae and prolonged 
exposure to harmful adverse effects of therapeutics [135-136]. Health-related Quality of 
Life (HRQOL) is defined as “optimum levels of mental, physical, role and social functioning, 
including relationships, and perceptions of health, fitness, life satisfaction and well-being,” 
incorporating the “assessment of patient’s satisfaction with treatment, outcome and health 
status and future prospects” [137]. Children with JSLE score poorly on HRQOL as compared 
to healthy children as well as those suffering from other chronic rheumatological 
conditions, in some domains of HRQOL [134]. Poor HRQOL has been found to positively 
correlate with JSLE disease activity and with accumulated irreversible organ system 
damage, with greater emphasis placed upon the physical than psychosocial domains [134]. 
Patients with active central nervous system (CNS), renal or musculoskeletal (MS) disease 
suffer from diminished HRQOL as compared to JSLE patients without [134]. These disease 
manifestations also offer a worse clinical prognosis. A previously un-noted but highly 
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significant finding was the effect of the disease process on family life, with increased 
disease activity and greater scores of accumulated irreversible damage having the most 
significant effect on family related domains [134]. 
Although many positive steps have been taken in improving the evidence base for the 
management of JSLE, much additional effort is needed. The recently developed advances in 
therapeutics are aimed at containment of the disease process but not cure. Although 
advancing life expectancy, the shortfalls of this approach are clear in the long-term 
morbidity faced by these patients. This highlights the need for more research into the 
aetiology of this chronic condition and a better understanding of the disease process. Once 
this occurs more effective targeted therapies can be engineered with the aim of curing the 
condition, or at least limiting the long-term morbidity that is currently a major issue in JSLE.   
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1.4 Summary 
JSLE is an inflammatory, multisystem autoimmune condition characterised by the 
production of autoantibodies directed against nuclear material. It is a more severe form of 
adult-onset SLE, with a more aggressive onset, clinical course and consequently has more 
severe implications for short and long-term morbidity and mortality. The condition is 
diagnosed according to the presence of at least 4 of 11 criteria under the age of 18, but 
typical onset is in females of adolescent age. It is thought to result from the overwhelming 
dysfunction of the immune system, resulting in immune cell hyper- and autoreactivity with 
abnormal complement and cytokine profiles thought to have a role. Dysregulated 
neutrophil apoptosis has also been implicated in the generation of nuclear auto-antigens in 
JSLE. Management is aimed at suppression of the immune system with steroids making up 
the mainstay of treatment, supplemented by other immunosuppressant’s and more 
recently developed biologic drugs. With the recent discovery of the TLR family and their 
ability to detect autoantigen much focus has shifted to their role in the pathogenesis of 
general autoimmunity and more specifically SLE. It has been found that there is up-
regulation of these receptors in SLE which positively correlates with disease activity, anti-
dsDNA titers and cytokine production. Despite these findings there are currently no studies 
assessing the role of TLRs in JSLE. 
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1.5 Hypothesis 
As well as recognising non-self nucleic antigens, some TLRs are also able to bind and be 
activated by endogenous nucleic autoantigens. Neutrophils may be a source of endogenous 
nucleic acid autoantigen due to increased apoptosis in JSLE.  
The hypothesis is therefore that apoptotic neutrophils in JSLE are providing a source 
nuclear autoantigen(s), which are being detected through the innate immune system by 
the TLR pathway, resulting in an inflammatory response through activation of an adaptive 
autoimmune response. 
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2 Methods 
2.1 Patients 
Written informed consent was obtained from all participating subjects or their 
parent/guardian. JSLE patients fulfilled the revised American College of Rheumatology 
criteria before the age of 17 years [51]. Juvenile Idiopathic Arthritis (JIA) patients acted as 
inflammatory controls and met the modified International League of Associations for 
Rheumatology (ILAR) classification criteria [138]. Paediatric non-inflammatory controls 
were children attending for day case procedures or those suffering from non-inflammatory 
musculoskeletal symptoms or attending for routine elective operations in who a history of 
autoimmunity and infection were excluded. Patients were attending Alder Hey Children’s 
National Health Service Foundation Trust. All patients were taking part in the “UK JSLE 
Cohort Study & Repository: Clinical characteristics and immunopathology of juvenile-onset 
systemic lupus erythematosus" for which full ethical (Research Ethics Committee number: 
06/Q1502/77) and Research & Development Departmental approvals were already 
granted. 
Samples were collected at the time of routine phlebotomy for clinical monitoring of disease 
activity. Between 5-10ml of blood was collected and transferred immediately to the 
laboratory according to the Cohort Study protocol. All study samples were anonymized 
following collection. 
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2.2 Cell Preparation 
2.2.1 Peripheral Blood Mononuclear Cell (PBMC) Isolation 
Each 5ml heparinised blood sample collected from participants was processed within two 
hours. The sample was added to an equal volume of Histopaque (Sigma-Aldrich, UK) and 
centrifuged (Thermo Electron, UK) at 1800rpm for 30 minutes without brake. This 
produced a clear band of PBMCs which were isolated manually using a pipette. The PBMCs 
were transferred to a 15ml tube to which 10ml of RPMI and glutamine (Sigma-Aldrich, UK) 
was added. This mixture was then centrifuged at 2000rpm for 10 minutes with brake, 
producing a pellet. The supernatant was poured off in a quick action and PBMCs were re-
suspended in the remaining RPMI residue. Either 1ml RPMI medium was added ready for 
TLR analysis or 250µl using 2% foetal calf serum (FCS) in 1xphosphate saline buffer solution 
(PBS) ready for B cell isolation. 
2.2.2 B Cell Isolation 
CD19+ B cell populations were separated using a negative selection immunomagnetic cell 
selection procedure using Easysep mAb magnetic nanoparticles and magnet (Stemcell 
Technologies Inc).  B cells were isolated from PBMCs (Section 2.2.1). All 250µl of sample 
was transferred to a 5ml polystyrene tube and 15µl of enrichment cocktail was added and 
incubated for 10 minutes at room temperature (RT). Secondly, 15µl of magnetic 
nanoparticles were added to the mixture and incubated for a further 10 minutes at RT. 
Finally the mixture was made up to 2.5ml using 2% FCS in PBS and placed in the magnet for 
5 minutes at RT. The B cells were then decanted into a fresh tube leaving the magnetised 
unwanted cells in the tube in the magnet. This method ensures the isolation of an 
unstimulated pure B cell population. 
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2.2.3 Neutrophil Isolation 
Neutrophils were also isolated from heparinised whole blood and samples were processed 
within two hours. The sample was added to an equal volume of Polymorph Prep (Axis 
Shield, Norway) and centrifuged at 1800rpm for 30 minutes without break. This produced 
two clear bands of cells (Figure 5). The uppermost band consisted of PBMCS and could be 
isolated using the same protocol as neutrophil isolation if required. The lower band was a 
neutrophil layer which was isolated manually using a plastic pipette. The neutrophils were 
transferred to a 15ml tube to which 10ml of RPMI and glutamine (Sigma-Aldrich, UK) was 
added and spun at 2000rpm for 10 minutes with brake producing a pellet. The supernatant 
was poured off in a quick action and neutrophils were re-suspended in the remaining RPMI 
residue. Contaminating erythrocytes were removed by hypotonic lysis using a 1 part RPMI 
medium, 9parts 1x ammonium chloride solution in which the PBMCs were incubated for 3 
minutes and centrifuged at 2000rpm for 5 minutes with brake. The supernatant was 
poured off in a quick action and neutrophils were re-suspended in the residue and made up 
to a total volume of 1ml using RPMI. Neutrophils were counted using a haemocytometer.   
Figure 5: Neutrophil isolation 
 
Before: Whole blood is layered on top of Polymorph Prep. After: Separation of PBMCs and 
neutrophils from whole blood by one step centrifugation 
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2.3 RNA Extraction 
RNA was extracted using the RNeasy miniprep kit (Qiagen, UK) following the 
manufacturer’s instructions. Briefly, the sample was transferred into a 1.5ml 
microcentrifuge tube and centrifuged at 8000rpm, 4°C for 10 minutes with brake, 
producing a cell pellet. All supernatant was removed leaving a dry pellet to which 350µl of 
RLT buffer + 0.1% β-mercaptoethanol was added. The mixture was vortexed before being 
transferred to a QIAshredder (QIAGEN) and centrifuged at >10,000rpm for 2 minutes. The 
filtrate was mixed with 70% ethanol and transferred to an RNeasy mini column (QIAGEN) 
and centrifuged for 15 seconds (s) at >10,000rpm. The filtrate was then discarded and the 
mini column was added to a fresh collection tube to which 700µl of RW1 buffer was added 
and centrifuged for 15s at >10,000rpm. The filtrate was discarded and mini column added 
to a fresh collection tube and 500µl of RPE buffer was added and centrifuged at 
>10,000rpm for 15s. This step was repeated but for a duration of 2 minutes. Finally the 
mini column was placed into a 1.5ml microcentrifuge tube, 40µl of RNase and DNase 
treated water was added and spun for 1 minute at >10,000rpm to elute the RNA. 
2.4 RNA Quantification 
Quality and concentration of RNA was determined by spectrophotometery using a Nano 
Drop 1000 spectrophotometer and software (Thermo Scientific, UK). The machine was 
blanked using 1µl of RNase-free water. Samples of RNA (1µl) were loaded and used to 
analyse the amount and quality of RNA present. Quantity was measured in ng/µl. Quality is 
expressed as the 260/280 ratio. This is a measurement of the value obtained at 260nm 
divided by the measurement taken at 280nm; a ratio below 1.7 suggests contamination 
while above 2.1 is indicative of degradation. If an acceptable reading was obtained the 
volume of RNA required to obtain a standardised concentration for all samples was 
calculated. After quantification RNA was stored at-80°C.  
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2.5 Reverse Transcription 
This process is implemented to synthesise a complementary strand of DNA (cDNA). 
Depending upon the quantity of the RNA, varying volumes of the sample were used to 
obtain a final concentration of 0.05µg of cDNA. To synthesise cDNA the calculated volume 
of RNA was added to 1µl of random primers (Promega, USA) and a volume of RNase free 
water was added to constitute a total volume of 15µl. The mixture was then placed in an 
AccuBlockTM (heatblock) digital dry bath (Labnet International, Inc; Rutland) preheated to 
70°C for 5 minutes. This process allowed random primers to anneal to random sequences 
of the RNA. Once this step was completed 5µl MMLV buffer (Promega, UK); 1.25µl dNTP’s 
at a concentration 10mM (Promega, UK); 0.5µl RNase inhibitor (Promega, USA); 1µl reverse 
transcriptase (Promega, USA) and 2.25µl of RNase free water was added to each sample 
and placed on the heatblock at 42°C for 1 hour. Once complete 75µl of RNase free water 
was added and the cDNA was immediately transferred into a -20°C freezer to prevent 
degradation. 
2.6 Quantitative Polymerase Chain Reaction  
The Polymerase Chain Reaction (PCR) is defined as “…the in vitro enzymatic synthesis and 
amplification of specific DNA sequences” [139]. It is an experimental method which allows 
the amplification and detection of a specific region of DNA from a single molecule of DNA. 
2.6.1 Theory 
From a single molecule of DNA it is possible to amplify over 1 billion copies of the target 
sequence. This is done using a pair of oligonucleotide primers which are complementary to 
opposite ends of the target sequence. The primers anneal to the target sequence and are 
extended by DNA polymerase, reproducing the target gene. This process is carried out in a 
3 step reaction cycle of denaturation, primer annealing, and polymerization.   
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2.6.1.1 Primers 
A primer is a DNA or RNA segment that is complementary to a specific DNA sequence and 
required to initiate replication by DNA polymerase. They are short oligonucleotide strands 
of between 18-30 nucleotides in length, which are designed to anneal to the flanking 
sequence of opposite strands of the target sequence. DNA polymerase then replicates the 
target sequence in the 5’ to 3’ direction producing complementary strands of the 
nucleotide sequence. These newly synthesised strands then act as templates for replication 
in later amplification cycles. 
2.6.1.2 PCR Cycle 
The basic PCR cycle consists of a 3 step cycle of denaturation, primer annealing and 
polymerization (Figure 6).  
Figure 6: The PCR Cycle 
 
Thermal profile and stages of the PCR cycle. Hot start is required to activate DNA polymerase. 
Amplification consists of a denaturation, primer annealing and polymerization stage. The last 
stage of the cycle generates a dissociation curve. 
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The PCR cycle begins with a 10 minute hot start at 95°C. This process is required to activate 
DNA polymerase which is chemically modified to ensure that the enzyme does not undergo 
activity prior to PCR. Once completed PCR amplification begins. This consists of a 3 step 
procedure, repeated over 40 cycles. Firstly the denaturation stage heats the DNA to 95°C 
for 15s, breaking the bonds maintaining helical structure, allowing the complementary 
strands to separate and the target sequence to become exposed [140]. Secondly the 
sample is heated to 60°C for 1 minute, allowing the primers to anneal to their flanking 
sequence, providing an attachment point for DNA polymerase [141]. Thirdly the sample is 
kept at 72°C for 30s during which DNA polymerase inserts nucleotides into the growing 
polymer chain until the complementary strand of the target sequence has been duplicated 
[141]. This 3 step cycle is repeated 40 times resulting in an exponential amplification of the 
target sequence in which the total amount of DNA is doubled per cycle. Once the PCR 
amplification stage is complete, the samples are heated to 90°C for 1 minute, 55°C for 30s 
and finally 95°C for 30s. This last stage generates a dissociation curve which is explained in 
greater detail in section 2.6.1.4.  
2.6.1.3 Detection 
Quantification of DNA is achieved by measuring the level of fluorescence of a given sample 
of DNA, with fluorescence increasing proportionally with quantity of DNA. SYBR Green is a 
dsDNA-binding dye which becomes incorporated into the amplified dsDNA during the 
polymerization (extension) phase of the PCR cycle (Figure 7) [142]. It has an undetectable 
fluorescence when unbound, but strongly emits its fluorescence when bound. Fluorescence 
is measured at the end of each of the 40 cycles and used to quantify the amount of dsDNA 
present. However as this dye lacks specificity it is crucial that the PCR reaction only 
contains the target amplicon, or that further analyses are employed, for example melting 
point analysis, to discriminate between products (Section 2.6.1.4) [143].  
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Figure 7: Mechanism of SYBR Green 
 
 
 
 
 
Denaturation exposes dsDNA allowing annealing of SYBR Green [144] 
 
2.6.1.4 Interpretation 
A standard curve is generated to measure the efficiency of the reaction. In theory each 
time an amplification cycle is completed the quantity of amplicon increases, therefore the 
level of fluorescence increases and is therefore detected sooner. If this occurs effectively 
the reaction is said to have 100% efficiency, for this study a range of 90-110% was 
considered acceptable. The standard curve is generated by plotting the points when 
fluorescence is detected in 5 ‘standards’, consisting of serially diluted samples, against the 
relative concentrations of those standards, using an arbitrary start point (Figure 8). With 
100% efficiency all values will fall on the line of correlation. 
This text box is where the unabridged thesis included the following 
third party copyrighted material: 
SYBR Green during PCR amplification 
 
Fraga D, M.T., Fenster S, Real-Time PCR, in Current Protocols  
Essential Laboratory Techniques. 2008, Wiley. 
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Figure 8: qPCR Standard Curve 
 
Standard curves are used to measure the efficiency of the reaction. 100% efficiency represents a 
perfect reaction 
Amplification plots are generated by plotting the fluorescence of the sample against the 
number of cycles (Figure 9). An arbitrary level of background fluorescence is set during 
cycles 3-15, usually determined as 10 times the standard deviation of the baseline and is 
known Ct [142]. The cycle number at which the reporter dye emission intensity rises above 
background fluorescence is called the Ct, this cycle number is recorded for each sample. As 
fluorescence is determined by quantity of dsDNA and each amplification doubles the 
amount of dsDNA in each sample, Ct value is dependent upon the initial quantity of 
material in the sample, therefore those containing greater quantities of dsDNA will have 
lower Ct values. An experiment consisting of identical samples of the same concentration 
should theoretically have identical Ct values. If a reaction is 100% efficient then this would 
be the case. 
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Figure 9: qPCR Amplification Plot 
 
Amplification increases dsDNA quantity and therefore fluorescence. Cycle threshold (Ct) value is 
measured as the cycle upon which fluorescence exceeds background fluorescence. 
The last cycle of the PCR process denatures the DNA double helix generating a dissociation 
curve (Figure 10). This step is carried out to ensure confidence that the fluorescence being 
detected is due solely to detection of the target sequence. The melting profile of a DNA 
duplex is dependent upon the surrounding buffer, the guanine-cytosine content, the length 
and the configuration of the nucleotide sequence [145]. As the SYBR green mastermix has 
been utilised in our protocol this nullifies the buffer variable as this will be standard across 
all of our samples therefore variables to take into account for the melting point will be 
specific to the properties of the target sequence. As we are assessing for just one target 
sequence the dissociation curve would be expected to have one clear peak as all of the 
dsDNA in the sample are exact replicas of the target sequence. If this is the case then the 
results obtained are reliable. However if there is more than one peak this indicates either 
contamination of sample, therefore the SYBR Green is detecting other dsDNA, or 
Baseline 
Threshold 
Ct value 
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alternatively dimerisation of the primers used (Figure 11). There are several techniques 
used to combat this problem for example setting the PCR software to detect fluorescence 
above the primer dimer’s melting temperature but below that of the product and good 
design of primers. 
Figure 10: qPCR Dissociation Curve 
 
Figure 11: Minor peak demonstrating primer dimerization 
 
There are many variables that must be controlled when utilising quantitative PCR as a 
reliable measurement of mRNA expression. Included in this list of variables are initial 
sample amount, RNA quality and concentration, efficiency of cDNA synthesis and 
fundamental differences in the biological activity of the target tissue [146]. To neutralize 
these confounders an internal control gene is used to normalize these variables. A good 
Primer Dimerization 
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internal control or ”housekeeping” gene must be universally expressed at a constant level 
in the tissue of interest and should not vary in expression between stages of development 
or be affected by experimental conditions [142]. The level of the target mRNA is then 
compared to the level of the housekeeping gene to provide a reliable normalised 
quantification of mRNA expression. 
Two internal control genes, 18s and β-actin, were tested for reliability. 18s is a ribosomal 
RNA subunit and is recommended as an internal standard for mRNA quantification [147]. β-
actin is a gene that is vital in maintaining and regulating the structure and kinetics of the 
cytoskeleton and is a popular housekeeping gene [147]. Our optimisation showed 18s to 
provide the most reproducible results and on this basis was selected as the internal control 
for our experiments. 
qPCR values were calculated by dividing the copy number of the target gene by the copy 
number of the internal standard (18s).  These figures represent individual sample data 
points. If an average was required an average copy number for each group eg. JSLE and 
control was calculated from the individual sample data points. Error bars represented the 
standard error of the mean and were generated by dividing the standard deviation of the 
group by the square root of the sample number.  
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2.7 Measuring TLR and IFN-α mRNA Expression 
Quantitative Real-Time Polymerase Chain Reaction (qPCR) was carried out using Stratagene 
MX3005PTM qPCR machine and MXPRO-MX3005PTM software (Agilent Technologies, UK 
Ltd). A plate template was first devised, consisting of a non-template control, standards 1-5 
and samples, all were tested in duplicate. RNase free water acted as the non-template 
control (NTC). Following optimisation to determine the concentration of template required 
it was determined that cDNA samples would be diluted (1:5) with RNase free water. 
Standards were pooled from samples, consisting of an equal aliquot of cDNA from each. 
Serial dilutions of the pooled standard were made to make 5 standards of varying 
concentrations (neat, 1:2, 1:5, 1:10 and 1:20) using nuclease free water as the diluent. 
Once prepared, 0.75µl of each reverse and forward primers (Table 2 for primer sequences 
(MWG- Biotech, Germany)), 12.5µl SYBR Green Mastermix (Stratagene, USA) and 6µl of 
RNase free water was added to each well. To this 5µl of the appropriate NTC, standard or 
sample was added. The plate was sealed and pulsed for 5 seconds and then set to run on 
the aforementioned qPCR program (Section 2.6.1.2). 
Table 2: Primer sequences for qPCR 
Primer 
Set 
Forward Sequence Reverse Sequence 
18s 5’-TCCGATAACGAACGAGACTC-3’ 5’-CAGGGACTTAATCAACGCAA-3’  
TLR3 5’-CCTGGTTTGTTAATTGGATTAACGA-3’ 5’-TGAGGTGGAGTGTTGCAAAGG-3’ 
TLR7 5’-TTACCTGGATGGAAACCAGCTACT-3’ 5’-TCAAGGCTGAGAAGCTGTAAGCTA-
3’ 
TLR8 5’-CAGAATAGCAGGCGTAACACATCA-3’ 5’-TGTCAAGGCGATTGCCACTGA-3’ 
TLR9 5’-TGAAGACTTCAGGCCCAACTG-3’ 5’-TGCACGGTCACCAGGTTGT-3’ 
IFN-α 5’-GGAGTTTGATGGCAACCAGT-3’ 5’-CTCTCCTCCTGCATCACACA-3’ 
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2.8 Flow Cytometry 
This is a quantitative analytical technique based on the principle that individual particles 
can be differentiated based on their size, intracellular composition, surface properties and 
structure. This is possible via an intricate system of light detectors and a laser. 
2.8.1 Background 
Upon examination of a sample by flow cytometry cells are channelled into a narrow 
specimen stream with each cell passing through the laser beam individually. The cell 
crossing the laser’s path causes disbursement of light which is dependent upon the size and 
granularity of the individual cell. The size of the cell is calculated by measuring the amount 
of that light continues forward once the cell has come into contact with the laser beam, 
this measurement is called the forward scatter (FSC) (Figure 12). The granularity of the cell 
is determined by the amount of light diverted at a 90° angle, termed side scatter (SSC) 
(Figure 12).  
2.8.2 Fluorescences    
Although information about the size and granularity of a cell is useful the scope of 
applications of flow cytometry is much broader than this due to the use of fluorescences. 
Fluorescent dyes are coupled with antibodies directed against a target protein to allow 
differentiation of particles by factors other than size and granularity. One of the most 
commonly used fluorochromes is fluorescein isothiocyanate (FITC) which when excited by 
light emits a wavelength of around 519nm. Using this information it is possible to 
manipulate a light detector to detect emissions of only this wavelength, therefore it can be 
confidently assumed that any fluorescence detected in this channel is due to antibody 
specific binding to the target protein (Figure 12). CD19 is a well known marker of B 
lymphocytes, therefore by conjugating FITC with a CD19 antibody and staining a sample of 
cells you will be able to determine which cells within the sample are B lymphocytes through 
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analysis of their size, granularity and fluorescence. This same principle is applied using 
different fluorochromes and light detectors set to different wavelength emissions. It is 
possible that by using fluorochromes with different wavelength emissions to dual stain 
cells.  
Figure 12: Theory of Flow Cytometry 
 
 
 
 
 
 
 
 
 
 
Light from a laser hits the cell. Beams of light that continue forward are detected and used to 
determine cell size (Forward Scatter). Beams of light that are disbursed by cell contents at a 90° 
angle are used to assess granularity (Side Scatter). Beams that hit fluorescent-conjugated 
antibodies excite the fluorochrome resulting in emission of light of a particular wavelength. Light 
detectors sensitive to this wavelength detect these emissions and can be used to quantify the 
level of the protein of interest (Adapted from Luttmann W [21]).  
2.8.3 Staining 
Staining of extracellular antigens is a simple process by which cells are incubated with the 
appropriate fluorescence-conjugated antibody, washed to remove any free antibody which 
would produce false positive background activity and then run through the flow cytometer. 
However intracellular staining is more complicated in that the cell must become porous 
enough to allow the antibody to bind to the antigen but not too porous as to become 
unstable. Although each individual protocol is different they are all based on 3 essential 
steps: fixation, permeabilization and antibody staining. Fixation is required to render the 
This text box is where the unabridged thesis included the following 
third party copyrighted material: 
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Luttman W, B.K., Kupper M, Myrtek D, Immunology.  
The Experimenter Series. 2006, London: Elsevier. 
45 
 
cell structure and its contents stable enough to allow permeabilization and maintain the 
structure of the target antigen so that the antibody can bind to its epitope. 
Permeabilization of the cell is necessary to perforate the cell membrane creating passages 
for the antibody to migrate to its target epitope. The sample is now stained with the 
appropriate antibody and is ready for testing. 
2.8.4 Measurement 
Once cells, stained or un-stained, have been prepared they will be run through the flow 
cytometer, the read out from the flow can be represented in many ways. Only methods 
relevant to this project will be discussed. A FSC/SSC dot plot can be used to determine 
different cell types by size and granularity (Figure 13A). Once the population of interest has 
been identified for example neutrophils it can be selected by gating the area on the graph 
and further analysed by comparing levels of fluorescence. Staining with a FITC-conjugated 
Annexin V antibody would allow the quantification of apoptosis in that group of 
neutrophils, by measurement of mean fluorescence intensity (MFI), as only those stained 
would appear in the relevant region of the graph (Figure 13B).   
Figure 13: Flow Cytometry Dot-plot 
 
Figure A. Flow cytometry dot-plot showing differentiation of cells from whole blood based on size 
and granularity [148]. Figure B. Demonstrates identification of apoptotic neutrophils by Annexin V 
staining. 
 
A B 
Neutrophils 
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2.9 Measuring TLR Protein Expression 
PBMCs were isolated from healthy controls (n=5) (Section 2.2.1). Each sample was split into 
5. The conditions measured were an unstained control; TLR3 expression; TLR8 expression; 
TLR9 expression and a FITC conjugated anti-mouse secondary antibody (R&D Systems, UK). 
FITC labelled anti-mouse IgG1 acted as the isotype control for TLR3, 8 and 9.The 1ml 
samples were transferred to a 5ml polystyrene tube and spun down at 1100rpm for 5 
minutes pelleting the PBMCs. Cell supernatant was poured off and the tube blotted in one 
smooth action and cells resuspended in the residue. 1ml of ice cold PBS with Bovine Serum 
Albumin (PBA) (PBS with 0.1% Bovine Serum Albumin and 0.05% Sodium Azide) was added 
to the suspension and spun for 5 minutes at 1300rpm, supernatant poured off and pellet 
resuspended. PBMCs were fixed with 4% formaldehyde in 1ml PBA for 15 minutes. A 
further 1 ml of PBA was added and the sample was spun down, supernatant poured off and 
tube blotted. Cells were resuspended and 0.5% Tween in 1ml of PBA was added and spun 
down, poured off and blotted. Cells were resuspended in residue and stained with 4µl of 
primary antibody and conjugated in the dark for 30 minutes at room temperature.  After 
this 0.5% Tween in 1 ml of PBA was added and sample was spun, supernatant poured off 
and tube blotted. If required, cells were now incubated with a fluorescent-conjugated 
secondary antibody and washed under the same conditions as the primary antibody.  Cells 
were then washed twice with PBA-0.5% Tween and suspended in 0.5% formaldehyde and 
MFI was analysed immediately by flow cytometry. Values were obtained by calculating the 
average MFI for Control, JSLE and JIA groups. Error bars represented the standard error of 
the mean and were generated by dividing the standard deviation of the group by the 
square root of the sample number. 
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2.10 Enzyme–Linked Immunosorbent Assay 
Enzyme-Linked Immunosorbent Assay (ELISA) is a quantitative assay with many 
applications. The theory is that by using enzyme-conjugated antibodies it is possible to 
quantify the amount of a given molecule within a sample. The general concept is that the 
molecule of interest is immobilized on a plate surface then incubated with an enzyme-
conjugated antibody specific to that molecule. A substrate is then added resulting in a 
colour change which when exposed to a light of a particular wavelength will fluoresce. The 
degree of fluorescence is proportional to the amount of molecule fixed to the plate which 
is in turn determined by the concentration of that molecule in the sample This fluorescence 
is referenced against the level of fluorescence of a given set of standards to produce a 
quantifiable measurement of the molecule of interest.  
2.10.1 Sandwich ELISA 
Although there are many variations of the ELISA method the Sandwich ELISA is generally 
regarded as the most sensitive (Figure 14) [21]. This involves the adsorption of an antibody 
or antigen to a high protein binding capacity plate, usually done by incubating the 
detection antibody overnight at approximately 2-8°C.  Once this has been completed free 
protein sites are blocked with a blocking reagent, for example Bovine Serum Albumin, to 
prevent non-specific binding which would result in potentially problematic background 
activity. The plate is then washed to remove any surplus or unwanted material. The 
standards, controls and samples are added to allow binding of the desired molecule and 
washed again to remove any unwanted material. An enzyme-conjugated detection 
antibody, with a separate target epitope to the capture antibody, is then bound to the 
capture antibody-antigen complex. The most popular conjugated enzyme is horseradish 
peroxidise due to its stability and reliability in obtaining reproducible results. The plate is 
washed for a final time and then substrate solution, for example tetramethylbenzidine 
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(TMB), is added resulting in a colour change. After a varying amount of time, dependent on 
the substrate employed, a stop solution such as H2SO4 is added to halt the reaction.  The 
ELISA should be measured as soon as possible within the following 30 minutes at the 
recommended wavelength with a photometer. 
  
49 
 
Figure 14: Sandwich ELISA 
 
  Capture antibody adheres to plate overnight. Free protein binding sites are blocked and 
standards, controls and samples, are added to plate. Once bound an enzyme-conjugated 
detection antibody is incubated and binds to the the complex. Addition of substrate leads to a 
colour change proportional to the original concentration. This colour changed is then 
measured using a photometer.  
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2.10.2 Analysing ELISAs 
The serially diluted standards are included in an ELISA to generate a standard curve (Figure 
15) as a measure of the efficiency of the reaction taking place. By adding standards of 
known concentrations you are able to anticipate the results you are going to obtain, for 
example increasing fluorescence with increasing concentration of standard. If this result is 
not obtained it can be assumed that another unknown variable has influenced the reaction 
therefore your readings for samples of unknown concentrations cannot be relied upon. The 
efficiency of reaction is expressed as the R2 value with 1.0 ± 0.1 representing the optimal 
efficiency. If the result is outside of this range then the experiment is not valid. 
Figure 15: ELISA standard curve generated from serially diluted standards 
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2.11 Measuring TLR Ligand Induced IFN-α Expression 
PBMCs were isolated from healthy controls (n=3) (Section 2.2.1). PBMCs were suspended in 
1ml of culture medium (RPMI + 10%FCS + 0.05% penicillin and streptomycin) and counted 
using a haemocytometer. Once counted each sample was made up into a dilution of 
500,00cells/ml of which 200µl of sample was added per well to a 96-well plate (Corning, 
NY, USA). For each sample there were 5 conditions consisting of TLR 3, 7, 8 and 9 ligand 
(Invivogen, San Diego) stimulated cells and a control condition comprising of 200µl of 
unstimulated PBMCs. All ligands were commercially bought and added at a dose within the 
manufacturers recommended reference range (Table 3). Cells and ligands were incubated 
for 6 hours at 37°C, after which all samples were transferred from their respective wells 
into microcentrifuge tubes and spun at 10,000rpm for 5 minutes at 4°C. This deposits the 
PBMCs at the bottom of the tube allowing the cell pellet and supernatant to be separated 
by pipetting. Cell supernatants were stored at -20°C. RNA was extracted (Section 2.3) from 
cell pellets, reverse transcription (Section 2.5) performed, synthesising cDNA.  
Table 3: TLR Ligand Doses 
Agonist Concentration 
3 (Poly I:C) 10µg/ml 
7 (Imiquimod) 1µg/ml 
8 (ssRNA) 1µg/ml 
9 (ODN 2216) 1.5µM 
 
2.11.1 Protein Expression 
IFN-α protein expression was measured by ELISA (eBioscience, USA). A 96-well microtiter 
plate (Nunc, Denmark) was incubated with 100µl/well of capture antibody at a 1/250 
dilution in coating buffer overnight at 4°C. The plate was sealed. The plate was washed 5 
times (as are all washes from this point unless stated) in 1xPBS, 0.05% Tween-20 and 
blocked with 200µl/well of 1x assay diluent for 1 hour at room temperature. After washing, 
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100µl/well of NTC, standard or sample is added. 1x assay diluent acts as the NTC and 
standards are serially diluted 2-fold 7 times in 1x assay diluent; both are added to the plate 
in duplicate. After optimization it was decided that cell supernatants were to be diluted 1:5 
in assay diluent and are also added in duplicate. NTC, standards and samples were 
incubated at room temperature for 2 hours. The plate was washed and 100µl/well of 
detection antibody at a 1/250 dilution was added and incubated at room temperature. 
After 1 hour the plate was washed and 100µl/well of Avidin-Horseradish Peroxidase was 
added at a 1/250 dilution and incubated at room temperature for 30 minutes.  The final 
wash was carried out 7 times and 100µl/well of TMB was added and incubated at room 
temperature. After 15 minutes 50µl/well of stop solution (2N H2so4) was added and the 
plate read by a photometer at 450nm (BioTek®, ELx800 Absorbance Microplate Reader).  
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2.12 Measuring IFN-α Expression of PBMCs Incubated with 
Neutrophils that have undergone Apoptosis in JSLE and Control 
Serum 
PBMCs and neutrophils were isolated from healthy controls (n=4) (Section 2.2.3). 
Neutrophils were counted and diluted in culture medium to a concentration of 
5x105cells/ml. The sample was then divided into two with half of the neutrophils incubated 
with 10% paediatric control serum and the other half incubated with 10% JSLE serum. All 
samples were incubated at 37°C. After 2 hours apoptosis was measured by flow cytometry 
using annexin V staining (Section 2.12.1). PBMCs were counted and diluted as neutrophils. 
Per well 100µl of PBMCs were incubated with 100µl of control serum induced apoptotic 
neutrophils or JSLE serum induced apoptotic neutrophils for 6 hours at 37°C. This 
incubation period proved to be optimal after testing of 6, 12 and 24 hour periods.  After 
this incubation period well contents were transferred into microcentrifuge tubes and spun 
at 10,000rpm for 5 minutes at 4°C. This allowed the separation of cells and supernatant. 
Cell RNA was extracted and reverse transcribed (Section 2.3 and 2.5). IFN-α mRNA 
expression was measured by qPCR normalised to18s mRNA expression (Section 2.7). 
2.12.1 Annexin V Staining 
A 400µl sample of neutrophils was transferred to a 5ml polystyrene tube and 1ml of HBSS 
(Invitrogen, UK) was added and spun at 1800rpm for 5 minutes. Supernatant was poured 
off and cell pellet resuspended to which 100µl of HBSS and 1µl of Annexin V (Sigma-Aldrich, 
UK) was added and incubated at 4°C in the dark for 15 minutes. Following this incubation 
1ml of HBSS was added to the sample and spun. Supernatant was poured off and cell pellet 
re-suspended, 600µl of HBSS was added to the sample and % apoptosis read immediately 
by flow cytometry. 
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2.13 Measuring whether PBMCs express a dose-response 
relationship to apoptotic neutrophils 
PBMCs and neutrophils were isolated from healthy controls (n=3) (Sections 2.2.1 and 
2.2.3). Cells were counted and diluted to a concentration of 5x105cells/ml. Neutrophils 
were incubated with 10% paediatric control serum or JSLE serum for 2 hours and apoptosis 
was measured (Section 2.12.1). The experiment consisted of 200µl of unstimulated PBMCs; 
200µl of control serum induced apoptotic neutrophils; 200µl of JSLE serum induced 
apoptotic neutrophils; 100µl PBMCs incubated with 50µl of control serum induced 
apoptotic neutrophils; 100µl PBMCs incubated with 50µl of JSLE serum induced apoptotic 
neutrophils; 100µl of PBMCs with 100µl of control serum induced apoptotic neutrophils; 
100µl of PBMCs with 100µl of JSLE serum induced apoptotic neutrophils; 100µl PBMCs 
incubated with 200µl of control serum induced apoptotic neutrophils and 100µl of PBMCs 
incubated with 200µl of JSLE induced apoptotic neutrophils, per sample. After a 6 hour 
incubation at 37°C cells were isolated (Section 2.11 and 2.3). IFN-α mRNA expression was 
measured by qPCR (Section 2.7). 
2.14 Measuring whether PBMC TLR Expression Correlates with 
Increasing Apoptosis 
PBMCs and neutrophils were isolated from healthy controls (n=4) (Sections 2.2.1 and 
2.2.3). Cells were counted and diluted to a concentration of 500,000cells/ml. Neutrophils 
were incubated with 10% JSLE serum at 37°C for 30 minutes, 1 hour and 2 hours, apoptosis 
was measured at each time point (Section 2.12.1).  100µl of PBMCs were incubated with 
200µl of apoptotic neutrophils from each time point for 6 hours. After incubation cells were 
isolated (Sections 2.11 and 2.3) and IFN-α mRNA expression was measured by qPCR 
(Section 2.7). Fold change in apoptosis from 30mins was compared against TLR mRNA 
expression. 
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2.15 TLR Inhibition Optimisation 
PBMCs were isolated from healthy controls (n=2), counted and diluted to a concentration 
of 500,000cells/ml. PBMCs (200µl) were incubated with a TLR agonist (Invivogen, San 
diego), TLR specific antibody (Invivogen, San Diego), TLR agonist + TLR specific antibody or 
TLR agonist + chloroquine on a 96 well plate (Corning, NY, USA).  TLR agonists (Section 2.11) 
and specific antibodies (Table 4) were added at doses within the recommended reference 
ranges. This was with the exception of a TLR8 specific antibody which was not available in 
the lab at the time. The experimental control consisted of 200µl of unstimulated PBMCs. 
Samples were incubated at 37°C for 6 hours, after which they were transferred to a 
microcentrifuge tube and spun at 10,00rpm for 5 minutes at 4°C. Supernatant and PBMCs 
were separated by pipetting. IFN-α expression was compared between conditions as a 
marker of TLR activation.  cDNA was formed from cell pellets (Section 2.3 and 2.5) and IFN-
α mRNA expression was measured by qPCR (Section 2.7). IFN-α protein expression was 
measured by ELISA (Section 2.11) using cell supernatants at a 1:5 dilution. 
Table 4: TLR Specific Antibody Doses 
TLR  Antibody Concentration 
3 10µg/ml 
7 7.5µg/ml 
9 10µg/ml 
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2.16 Measuring TLR Inhibited IFN-α Expression in TLR9 and 
Apoptotic Neutrophil Stimulated PBMCs  
MyD88 is a common TLR adapter protein and is vital to the pathway of TLR 7, 8-9. PBMCs 
were isolated from healthy controls (n=5) (Section 2.2.1) counted and made into a 
concentration of 500,000cells/ml in culture medium (Section 2.11). Each sample was split 
into 5 conditions; 200µl of unstimulated PBMCs; 200µl of MyD88 inhibited PBMCs 
stimulated with TLR9 ligand; 200µl PBMCs stimulated with TLR9 ligand; 100µl of MyD88 
inhibited PBMCs incubated with 200µl of apoptotic neutrophils and 100µl of PBMCs 
incubated with 200µl of apoptotic neutrophils. TLR inhibition was obtained by incubating 
PBMCs with MyD88 inhibitory peptide at 100µM for 12 hours. Neutrophils were isolated 
counted and diluted to a concentration of 500,00cells/ml as PBMCs and incubated in 10% 
JSLE serum for 2 hours to induce apoptosis. After 2 hours neutrophil apoptosis was 
measured by flow cytometry using Annexin V staining (Section 2.12.1). Apoptotic 
neutrophils and TLR9 ligand (Section 2.10) were added to the appropriate wells and 
incubated for 6 hours. After this incubation the well contents were pipetted into individual 
microcentrifuge tubes and spun at 10,000rpm for 5 minutes at 4°C pelletting the cells and 
allowing the separation of cells and supernatant. RNA was extracted from the cells (Section 
2.3) and IFN-α mRNA expression was measured by qPCR and normalised to 18s mRNA 
expression (Section 2.7).  
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2.17 Statistical Analysis 
All statistical analyses were carried out by the author using standard statistical tests using 
SPSS Version 18.01. Two-tailed tests were carried out in all analyses with significance set at 
the p<0.05 level. For analyses of experiments carried out on all three patient groups (JSLE, 
JIA and healthy controls), once raw data was obtained, the Kruskal Wallis non-parametric 
test was employed to detect any significant differences within the data between groups. If 
a significant value was obtained (p<0.05) the non-parametric Mann-Whitney U test was 
used to analyse for statistically significant differences between study groups/non-paired 
groups/samples. Regression analyses were used to identify any significant associations in 
trends. 
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3 Results 
3.1 Demographics 
The study involved 32 patients with JSLE and 17 patients each for both the JIA 
inflammatory control group and paediatric healthy control group, mean age was 11.8 
(range 3-17.4), 10.7 (3.1-17.6) and 12.3 (6.1-16.4) years, respectively. Groups contained a 
similar male:female ratio (JSLE 38% male, JIA 41%, healthy controls 47%) and were made 
up of predominantly white British patients (exceptions: JSLE 7 Indian, 2 white other, 2 
Bangladeshi, 2 Pakistani and 1 not stated; Healthy controls 2 Chinese and  1 white other).  
Table 5 summarises clinical biomarker data of disease activity for the JSLE patients, 
indicating mild to moderate/severe activity at time of sampling. Table 6 shows data on the 
medications used in our JSLE study population at time of sampling. 
Of the 17 JIA patients studied 7 (41%) had systemic-onset; 4 (24%) had polyarticular 
disease; 4 (24%) had oligoarticular disease; 1 psoriatic (6%) and no details of specific sub-
class of JIA was available for 1. JIA core set criteria for disease activity [149] were as 
follows: mean number of joints with reduced range of motion was 1.2 (range 0-6) and 
mean number of swollen joints was 2.5 (0-18) across all JIA subtypes; mean scores for 
erythrocyte sedimentation rate ESR was 14.82 (1-55); Childhood Health Assessment 
Questionnaire (C-HAQ) score was 0.96 (0-2.125) and the patients/parent’s assessment of 
pain was 26.1 (0-80) using a 0-100m visual analogue scale. Data on medications used in our 
JIA study population at time of sampling is shown in Table 6. 
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Table 5: JSLE Disease Activity Data 
Biomarker/disease activity parameter 
(Normal range) 
Juvenile-onset SLE 
patients* 
(n=32) 
 ESR, mm/hour  
(normal 2-8mm/hour) 
17.5 (1-87) 
CRP, mg/litre            
(normal 0-8mg/litre) 
9.3 (4-71) 
Total WBC count, x109/litre 8.6 (2.5-26.3) 
Neutrophil count, x109/litre 5 (1.31-15.57) 
Lymphocyte count, x109/litre 2.7 (0.09-13.68) 
     Complement, gm/litre  
 C3  
(normal 1.10-1.98) 
1.1 (0.68-1.51) 
 C4 
 (normal 0.19-0.56) 
0.2 (0.12-0.38) 
Anti-dsDNA titre, IU/ml   
     (<7) 
21.8 (0-280) 
IgG, gm/litre  
(normal 7.39-13.9) 
12.5 (3.4-21.29) 
Global BILAG-2004 Score 2.9 (0-17) 
 
 
 
  
*Mean (Range); ESR = Erythrocyte Sedimentation Rate; CRP = C-reactive Protein; WBC = 
White Blood Cell; Anti-dsDNA = anti-double stranded DNA; BILAG = British Isles Lupus 
Assessment Group 
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Table 6: JSLE and JIA Medication 
Current medications, no. of patients* (%) JSLE JIA 
     Hydroxychloroquine 21 0 
     Methotrexate 3 6 
     Azathioprine/Cyclosporin 5 0 
     Mycophenolate mofetil 7 0 
     Prednisolone 19 9 
     Prednisolone dosage, mean   
     (range) mg/day 
19.3 (5-60) NA 
     Previous cyclophosphamide 5 0 
     Intravenous immunoglobulin 3 2 
     Biologics 0 12 
     NSAIDs 0 6 
     Other 0 5 
 
 
 
 
  
*Patients may be on >1 medication; JSLE = Juvenile Systemic Lupus Erythematosus;           
JIA = Juvenile Idiopathic Arthritis; NA = Not available 
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3.2 TLR Expression in JSLE 
3.2.1 TLR mRNA Expression in PBMCs 
PBMCs were isolated from whole blood from JSLE (n=7) and JIA (n=7) patients and healthy 
controls (HC) (n=6). TLR mRNA expression was measured by qPCR, normalised to 18s mRNA 
expression (Figure 16). There was a statistically significant increase in TLR 3 (HC p=0.001), 8 
(HC p<0.001) and 9 (HC p=0.003; JIA p=0.036) mRNA expression in JSLE compared to 
controls. TLR 7 mRNA expression was higher in JSLE than controls but was not statistically 
significant (p=0.974). 
3.2.2 TLR Protein Expression in PBMCs 
PBMCs were isolated from whole blood from JSLE (n=5) and JIA (n=5) patients and healthy 
controls (n=5). TLR protein expression was determined by FITC labelled TLR specific 
antibody detection via flow cytometry (Figure 17 & 18). Isotype control MFI was 
comparable to unstained PBMCs.  It was found that TLR 3 protein expression was 
significantly increased in JSLE compared to HC (p=0.009) and JIA (p=0.016) patients, as was 
TLR 8 (HC p=0.009; JIA p=0.009) and TLR 9 (HC p=0.009; JIA p=0.009) protein expression 
(Figure 19). Interestingly TLR 3 (p=0.009) and TLR8 (p=0.028) protein expression was 
significantly increased in JIA as compared to healthy controls. 
3.2.3 TLR mRNA Expression in B Cells 
B cells were isolated from JSLE (n=7) and JIA (n=7) and healthy controls (n=4). TLR mRNA 
expression was measured by qPCR and normalised to 18s mRNA expression (Figure 20). It 
was found that TLR 7 (p=0.038) and 9 (p=0.038) mRNA expression was significantly higher 
in JSLE compared to healthy controls. TLR 3 and 8 mRNA expression was higher in JSLE 
compared to healthy controls but this difference was not significant (p=0.097 and p=0.073 
respectively). 
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Figure 16: PBMC TLR mRNA Expression 
   
   
PBMC TLR mRNA expression normalised to 18s mRNA expression in JSLE (n=7), JIA (n=7) 
and healthy controls (HC) (n=6). PBMCs were isolated from whole blood and mRNA 
expression was measured by qPCR. A TLR 3 mRNA expression was statistically significantly 
higher in JSLE compared to controls (HC p=0.001); B TLR7 mRNA was higher in JSLE 
compared to controls (p=0.974); C TLR8 mRNA expression was statistically significantly 
higher in JSLE compared to controls (HC p<0.001); D TLR9 mRNA expression was statistically 
significantly higher in JSLE compared to controls (p=0.003) and JIA (p=0.036). Values are the 
mean ± Standard Error of the Mean (SEM). 
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TLR Protein Detection 
Figure 17: PBMC Scatter Profile 
 
Flow cytometry scatter profile showing the PBMC cell population (A) gated for analysis.  
Figure 18: Identification of TLR Protein Expression 
 
A Unstained cells acted as the experimental control. Analysis of these cells by flow 
cytometry demonstrated them to not emit auto-fluorescence  B FITC-labelled TLR 3 stained 
PBMCs were shown to emit significantly more fluorescence than unstained cells 
(MFI=81.48). Measurements for TLR 7 and 9 were assessed and analysed in an identical 
manner. 
  
A B 
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Figure 19: PBMC TLR Protein Expression 
 
 
 
Analysis of MFI by flow cytometry of PBMC TLR protein expression in JSLE (n=5), JIA (n=5) 
and healthy controls (n=5), following staining with TLR 3, 8 & 9 fluorescent antibodies.  A 
TLR3 protein expression was statistically significantly increased in JSLE compared to control 
(p=0.009) and JIA (p=0.016). B TLR8 protein expression was statistically significantly 
increased in JSLE compared to control (p=0.009) and JIA (p=0.009). C TLR9 protein 
expression was statistically significantly increased in JSLE compared to control (p=0.009) 
and JIA (p=0.009). Values are the mean ± Standard Error of the Mean (SEM). 
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Figure 20: TLR mRNA Expression in B Cells 
   
   
B cell TLR mRNA expression normalised to 18s mRNA expression in JSLE (n=7), JIA (n=7) and 
healthy controls (n=4). B cells were isolated from whole blood and mRNA expression was 
measured by qPCR. A TLR 3 mRNA expression was higher in JSLE compared to controls 
(p=0.097); B TLR7 mRNA was statistically significantly higher in JSLE compared to controls 
(p=0.038); C TLR8 mRNA expression was higher in JSLE compared to controls (p=0.073); D 
TLR9 mRNA expression was statistically significantly higher in JSLE compared to controls 
(p=0.038). Values are the mean ± Standard Error of the Mean (SEM). 
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3.3 TLR Stimulation 
3.3.1 TLR Ligand induced IFN-α mRNA Expression 
Control PBMCs were stimulated with commercially available specific TLR 3, 7, 8 and 9 
ligands. After 6 hours PBMCs were harvested and TLR mRNA expression was measured and 
normalised to 18s. TLR 3 (x1.4 fold), 7 (x1.2), 8 (x2.4) and 9 (x3.78) induced IFN-α mRNA 
expression was increased compared to unstimulated PBMCs (control) (Figure 21A).  
3.3.2 TLR ligand induced IFN-α Protein Expression 
PBMCs were isolated from healthy controls (n=4) and stimulated with specific TLR 3, 7, 8 
and 9 ligands. After 6 hours cell supernatant was collected and IFN-α protein expression 
was measured by ELISA. IFN-α protein expression under TLR 3 (x1.2 fold), 8 (x1.2) and 9 
(x1.9) stimulation was increased compared to control (unstimulated PBMCs) (Figure 21B). 
3.3.3 Assay Limitations 
When measuring IFN-α mRNA expression there was considerable individual sample 
variation (Figure 22). This was not the case with measuring protein expression. It was 
thought that increasing the sample size would be an effective strategy in overcoming this 
biological variation. However this was found to be impossible due to problems with the 
efficiency of reaction of the subsequent qPCRs.  
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Figure 21: TLR Ligand Induced IFN-α mRNA Expression 
 
 
Control PBMCs (n=4) were stimulated with specific TLR agonists for 6 hours. A. RNA was 
extracted and IFN-α mRNA expression was measured by qPCR. IFN-α expression was higher 
in TLR 3 (x1.4 fold), 7 (x1.2) 8 (x2.4) & 9 (x3.78) stimulated compared to unstimulated 
PBMCs. B. Supernatant was isolated and IFN-α protein expression was measured by ELISA.  
IFN-α expression was higher in TLR 3 (x1.2 fold), 8 (x1.2) & 9 (x1.9) stimulated cells 
compared to unstimulated PBMCs. Values are the mean ± Standard Error of the Mean 
(SEM).  
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3.3.3.1 Assay Limitations 
Figure 22: Individual variation between samples 
 
 
Graphs displaying individual variation TLR induced IFN-α mRNA response within samples.    
PBMCs (n=4) were stimulated with each TLR 3, 7, 8 and 9 ligands for 6 hours. After 
incubation RNA was extracted and qPCR was used to determine IFN-α mRNA expression. 
The graphs above show that there was considerable individual variation with each TLR 
ligand.  
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3.4 Apoptotic Neutrophils Induce IFN-α 
3.4.1 JSLE serum induces increased apoptosis compared to control 
Neutrophils were isolated from whole blood and incubated with 10% JSLE or control serum 
for 2 hours. Apoptosis was measured using FITC conjugated Annexin-V staining (Figure 23). 
Figure 23: Dot plot showing % apoptosis of samples 
 
 
Percentage apoptosis was measured by flow cytometry following incubation of PBMCs with 
JSLE or control serum for 2 hours and staining with FITC-labelled annexin V. Incubation of 
control neutrophils with JSLE serum (B) results in increased apoptosis (17.7%) compared to 
control (A) (4.3%).  
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3.4.2 Neutrophils that undergo apoptosis in JSLE serum induce a greater IFN-α 
response from PBMCs than neutrophils incubated in control serum 
PBMCs and neutrophils were isolated from healthy controls (n=5). Neutrophils were 
incubated with either control or JSLE serum to induce apoptosis. After 2 hours apoptotic 
neutrophils were incubated with PBMCs. After 6 hours PBMCs were harvested and IFN-α 
mRNA expression was measured, normalised to 18s. Neutrophils that had undergone 
apoptosis in JSLE serum induced a greater IFN-α mRNA expression in PBMCs (x4.8 fold) 
than those incubated in control serum (Figure 24). 
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Figure 24: Neutrophils that undergo apoptosis in JSLE serum induce a greater IFN-α 
response from PBMCs than neutrophils incubated in control serum 
 
Control neutrophils (n=5) were incubated with control serum or JSLE serum for 2 hours. 
These apoptotic neutrophils were incubated with control PBMCs for 2 hours. Cell RNA was 
extracted and IFN-α mRNA measured by qPCR. PBMCs incubated with neutrophils that had 
undergone apoptosis in JSLE serum induced a greater IFN-α mRNA (x4.8 fold) response 
than those incubated in control serum. 
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3.4.3 Dose Response Relationship 
PBMCs and neutrophils were isolated from healthy controls (n=3). PBMCs were incubated 
with neutrophils that had undergone apoptosis in JSLE serum and control serum at varying 
concentrations. PBMCs and neutrophils were incubated at a concentration ratio of 1x105 
PBMCs: 5x104 neutrophils (2:1 ratio), 1x105 PBMCs: 1x105 neutrophils (1:1) and 1x105 
PBMCs: 2x105 neutrophils (1:2) respectively. 200µl of unstimulated PBMCs acted as the 
experimental control. After 6 hours PBMCs were harvested and IFN-α mRNA expression 
was measured by qPCR. All groups expressed a significantly higher IFN-α mRNA expression 
as compared to un-stimulated PBMCs (2:1, p=0.02; 1:1, p=0.02; 1:2, p=0.02). It was found 
that IFN-α mRNA expression occurred in a dose response manner to the concentration of 
apoptotic neutrophils. IFN-α mRNA expression was significantly higher in the 1:2 group as 
compared to the 2:1 group (p=0.035) (Figure 25). Neutrophils incubated in control serum 
and neutrophils incubated in JSLE serum express very little IFN-α mRNA. 
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Figure 25: Dose Response Relationship 
 
Control PBMCS (n=3) were incubated with varying concentrations of neutrophils that had 
undergone apoptosis in JSLE serum or control serum (2:1=1x105 PBMCs: 5x104 neutrophils; 
1:1 =1x105 PBMCs: 1x105 neutrophils; 1:2=1x105 PBMCs: 2x105 neutrophils). After 6 hours 
PBMCs were isolated and IFN-α mRNA expression was measured by qPCR. PBMC IFN-α 
mRNA expression occurs in a dose-response manner to apoptotic neutrophil concentration. 
IFN-α mRNA expression was significantly higher in the 1:2 group as compared to the 2:1 
group (p=0.035). Neutrophils incubated in control serum (Control npl) and neutrophils 
incubated in JSLE serum (JSLE npl) express little IFN-α mRNA. 
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3.5 % Apoptosis correlates with TLR mRNA Expression 
PBMCs and neutrophils were isolated from healthy controls (n=4). Neutrophils were 
incubated with 10% JSLE serum for 30 minutes, 1 hour and 2 hours and % apoptosis 
measured by flow cytometry. PBMCs were incubated with neutrophils at different % 
apoptosis. After 6 hours cell RNA was extracted and TLR 3, 7, 8 and 9 mRNA expression was 
measured by qPCR. It was found that there was a statistically significant positive correlation 
between increasing apoptosis and TLR 3 (p=0.004), 7 (p=0.006), 8 (p=0.14) and 9 (p=0.003) 
mRNA expression (Figure 26).  
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Figure 26: % Apoptosis correlates with TLR mRNA expression 
   
   
Control PBMCs and neutrophils were isolated for healthy controls (n=4). Neutrophils were 
incubated in 10% JSLE serum to induce apoptosis. After 30 minutes, 1hour and 2 hours % 
apoptosis was measured by annexin V staining through flow cytometry. PBMCs were 
incubated with neutrophils of varying % apoptosis for 6 hours. Post incubation TLR 3, 7, 8 
and 9 mRNA expression was measured by qPCR. PBMC TLR 3 (p=0.004), 7 (p=0.006), 8 
(p=0.014) and 9 (p=0.003) mRNA expression increases as apoptosis of neutrophil incubated 
with increases. 
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3.6 TLR Inhibition  
3.6.1 Optimization  
PBMCs were isolated from healthy controls (n=2). TLR specific inhibition was attempted 
using specific TLR antibodies, in the hope that this would inhibit activation, and 
chloroquine, a pan-inhibitor of TLRs. PBMCs were cultured with a specific TLR agonist, the 
specific TLR antibody, TLR agonist + specific TLR antibody or TLR agonist + chloroquine. It 
was found that there was considerable variation in response to ligand and specific 
antibodies between individuals (Figure 27). In some cases addition of antibody caused a 
greater IFN-α response than stimulation with the natural ligand itself. Equally, addition of 
chloroquine gave variable results, possibly due to need to further determine optimal 
concentrations of chloroquine and / or inability to inhibit commercial ligands used. 
Significant time and energy was spent trying to optimise these assays. However, mixed and 
at times conflicting responses indicate additional experiments are still needed to determine 
the appropriate inhibitors for these assays and concentrations of them. These further 
experiments unfortunately went beyond the time limits of this thesis. It was decided that 
as such, it was inappropriate to use these methods of TLR blocking for future experiments 
for the time being.  
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Figure 27: TLR Inhibition Optimization 
 
 
 
PBMCs (n=2) were incubated with TLR ± TLR specific antibody or Chloroquine for 6 hours, 
after which supernatant was isolated and IFN-α protein was measured by ELISA. Graphs 
demonstrate ineffectiveness of TLR antibody and chloroquine. On all accounts addition of 
TLR antibody failed to reduce IFN-α production significantly or to the level of control. 
Addition of chloroquine also failed to reduce IFN-α production. These results indicated that 
this method of TLR inhibition would be unsatisfactory for future inhibition assays. 
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3.6.2 MyD88 TLR inhibition decreases TLR induced IFN-α production n PBMCs 
PBMCs and neutrophils were isolated from healthy controls (n=5). PBMCs were stimulated 
with TLR9 ligand ± MyD88 inhibitor or apoptotic neutrophils ± MyD88 inhibitor or left 
unstimulated. MyD88 is a TLR adapter protein vital to the pathway of TLRs 7-9, therefore 
blockade of this pathway should inhibit their function. It was found that incubation with 
TLR9 ligand (p=0.009) or apoptotic neutrophils (p=0.009) significantly increased IFN-α 
mRNA expression in PBMCs compared to unstimulated PBMCs. Concomitant stimulation 
with MyD88 inhibitor and TLR9 ligand (x2.77 fold reduction; p=0.047) or MyD88 inhibitor 
and apoptotic neutrophils (x4.5 fold reduction; p=0.076) resulted in a decreased IFN-α 
mRNA expression than PBMCs stimulated with TLR9 or apoptotic neutrophils alone (Figures 
28 & 29).  
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Figure 28: MyD88 TLR Inhibition Decreases TLR 9 Induced IFN-α production in PBMCs 
 
Control PBMCs (n=5) were incubated with TLR9 agonist ± MyD88 inhibitor. PBMCs were 
incubated for 12 hours with MyD88 inhibitor prior to 6 hour exposure to TLR9 agonist. 
After incubation PBMCs were isolated and RNA extracted. IFN-α mRNA was measured by 
qPCR and normalised to 18s mRNA. It was found that incubation with TLR9 agonist 
(p=0.009) alone resulted in a significantly increased IFN-α mRNA expression compared to 
unstimulated cells. MyD88 inhibitor directed TLR blockade resulted in a significantly 
decreased IFN-α mRNA expression in PBMCs incubated with TLR9 ligand (x2.77 fold 
decrease; p=0.047) as compared to those not incubated with the MyD88 inhibitor. Markers 
are individual data points, black bar represents the mean. 
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Figure 29: MyD88 TLR Inhibition decreases IFN-α production in PBMCs incubated with 
Apoptotic Neutrophils 
 
Control PBMCs (n=5) were incubated with apoptotic neutrophils (AN) ± MyD88 inhibitor or 
left unstimulated. PBMCs were incubated for 12 hours with MyD88 inhibitor prior to 6 hour 
exposure to AN. After incubation PBMCs were isolated and RNA extracted. IFN-α mRNA 
was measured by qPCR and normalised to 18s mRNA. It was found that incubation with AN 
(p=0.009) alone resulted in a significantly increased IFN-α mRNA expression compared to 
unstimulated cells. MyD88 directed TLR inhibition resulted in decreased IFN-α mRNA 
expression in PBMCs incubated with AN (x4.5 fold; p=0.074) as compared to those not 
incubated with the MyD88 inhibitor. Markers are individual data points, black bar 
represents the mean. 
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4 Discussion 
4.1.1 Rationale for the study and its aims 
With the discovery of the TLR family and subsequent realisation of their fundamental 
importance to the immune response they have attracted much interest in their possible 
role in the development of disease, particularly autoimmune disease. The rationale behind 
this is that as they are responsible for the detection and propagation of a normal immune 
response against exogenous antigen, they may also be responsible for the detection of 
endogenous antigen resulting in a misguided immune reaction against host tissues. This 
theory is particularly relevant in those autoimmune conditions in which autoantibodies 
play a dominant role.  
TLRs are part of a larger family of pattern recognition receptors (PRR) whose specific role is 
as the first line of defence against invading pathogen. Once an antigen is detected its 
antigenic epitope is internalised and then displayed on the cell surface to cells of the 
adaptive immune system which mount an antigen specific response. Therefore it is 
plausible that if PRRs were mistakenly detecting autoantigen subsequently leading to its 
presentation as pathogenic, then an adaptive immune response could be mounted against 
this autoantigen, resulting in autoimmunity. This specific autoimmune response would 
include the production of autoantibodies targeted towards the offending autoantigen.  This 
theory has been supported by work showing synovial TLR mRNA expression in rheumatoid 
arthritis and monocyte TLR protein expression in anti-phospholipid syndrome to be 
increased [150-151]. These data support the hypothesis proposing their role in autoantigen 
detection in these diseases.  
The interest in the role of TLRs, particularly 3, 7, 8 and 9, in JSLE comes from the 
identification of their natural ligands [32]. These receptors are responsible for the 
detection of nucleic acid derived material, including for example dsDNA. JSLE is the 
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archetypal autoimmune condition with autoantibodies directed towards nuclear material. 
It is characterised by autoantibody production including anti-nuclear antibodies and 
autoantibodies directed against other encapsulated nuclear antigens such as anti-Ro, anti-
La, anti-RNP, and anti-Sm antibodies, but most importantly anti-dsDNA antibodies, whose 
titres have been shown to correlate well with disease activity and TLR expression [32, 125]. 
The data appears especially notable for TLR9 for which dsDNA is its natural ligand. There is 
some evidence in adult-onset SLE that TLRs may have a role in the pathogenesis of this 
condition [32-33, 124-126]. However to date there has been no exploration of their role in 
JSLE despite its more severe disease presentation and phenotype. Increased and 
dysregulated neutrophil apoptosis noted in JSLE may offer a potential source of increased 
endogenous nucleic acid autoantigen in JSLE.  
The role of TLRs in JSLE may therefore offer unique insight into the aetiopathogenesis of 
lupus.  
The hypothesis therefore to be studied was that apoptotic neutrophils in JSLE are providing 
a source of nuclear auto-antigen(s), which are being detected through the innate immune 
system by the TLR pathway leading to the induction of an inflammatory response through 
activation of an adaptive autoimmune response. 
The aim of this project was to assess their role by primarily analysing their expression and 
further to this examine whether they are capable of detecting a potential source of auto-
antigen in JSLE. 
The steps to explore this initially involved measuring TLR mRNA and protein expression in 
JSLE PBMCs and B cells, and comparing them to another paediatric autoimmune 
inflammatory rheumatological condition, JIA, and healthy paediatric controls.  
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Once dysregulated homeostasis was established, their potential role in the pathogenesis of 
the condition was investigated. TLR activation was assessed in response to their natural 
ligands. This same method of measurement was used to assess their activation in response 
to a potential source of JSLE autoantigen, namely the apoptotic neutrophil. Finally, TLR 
inhibition in the presence of the potential autoantigen was carried out to further validate 
their role in detection and response to apoptotic material in JSLE.   
4.1.2 Summary of Findings 
Examination of TLR expression in JSLE demonstrated significantly increased expression of 
TLRs 3, 8 & 9 at both the mRNA (Section 3.2.1) and protein (3.2.2) level in JSLE PBMCs 
compared to controls (JIA and healthy controls). Further to this it was found that B cells, 
capable of antigen presentation, also displayed significantly increased mRNA expression of 
TLRs 7 and 9 (Section 3.2.3). These findings confirmed an irregularity in TLR homeostasis in 
JSLE in those TLRs which are characterised by their ability to detect nuclear autoantigens. 
The hypothesis proposed that apoptotic neutrophils may act as a potential source of ligand 
for these TLRs, leading to downstream upregulation of signalling. Therefore, measuring 
IFN-α expression from PBMCs exposed to TLR ligands (naturally occurring) and following 
co-culture with apoptosing neutrophils (potential source of nucleic autoantigens) was used 
to determine whether TLR activation was taking place. Incubation of PBMCs with their 
natural ligands (commercially available) did stimulate increased production of IFN-α 
(Section 3.3). Importantly, apoptotic neutrophils also increased PBMC IFN-α mRNA and 
protein expression (Section 3.4.2). This was found to occur in a dose-response manner with 
IFN-α production increasing as relative concentration of apoptotic neutrophils increased 
(Section 3.4.3). These findings strongly supported the hypothesis that apoptosing 
neutrophils may be triggering TLR stimulation through presentation of autoantigens. 
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Further evidence to support the role of TLRs in inducing this IFN-α production in response 
to apoptotic material was the observation that TLR mRNA showed significant positive 
correlation with increasing neutrophil apoptosis (Section 3.5). From this it could be 
hypothesised that this increase in TLR expression is due to increasing availability and 
therefore access to nuclear autoantigens leading to greater activation of TLRs.   
Finally, the specific role of TLR activation by apoptotic neutrophils leading to the increase of 
IFN-α mRNA was demonstrated by a marked decrease in IFN-α response after inhibition of 
TLRs 7, 8 and 9 through the blocking of MyD88 (Section 3.6.2), a downstream adapter 
protein vital to these TLRs.     
4.1.3 Integration of study findings with existing evidence base in lupus 
The findings of this study are consistent with prior studies and strengthen the evidence 
base for demonstrating the role of TLRs in the pathogenesis of JSLE. In addition, it has 
added important new data on the mechanistic pathway leading to TLR activation. Devising 
new strategies for exploring the role of TLRs in autoantigen detection, the study has 
provided new evidence for a potential source of auto-antigen exposure in JSLE through 
dysregulated neutrophil apoptosis. 
The study demonstrated significant up-regulation of TLRs 3, 8 and 9 in PBMCs in JSLE. This 
is in concordance with work focusing on adult SLE which have shown significantly increased 
expression of these same TLRs at the protein and mRNA level [34, 124-125]. This present 
study also demonstrated increased TLRs 7 and 9 mRNA expression in JSLE B cells, consistent 
with a number of studies in adult-onset SLE [32-34, 124].  
The hypothesis that TLR activation leads to downstream effects important in the 
generation of the disease phenotype of lupus is supported by a case report describing the 
remission of long-standing SLE post development of an acquired deficiency of the TLR7 and 
9 signalling pathway in peripheral B cells [123]. The same acquired immunodeficiency has 
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been documented in 18 SLE patients with clinical improvement occurring in 12 of these 
[152]. Dual inhibition of these pathways has also been shown to block an inflammatory 
response in pDCs and autoantibody production in lupus prone mice [153-154]. The 
increased TLR expression in SLE PBMCs and B cells has been shown to correlate well with 
parameters of disease activity including the SLEDAI score and more specifically anti-dsDNA 
titres, with stimulation of TLR9 being shown to directly lead to anti-dsDNA production [33, 
125]. This evidence strongly suggests causality between increased TLR9 activation in vivo 
and anti-dsDNA production, which is thought to cause tissue damage in SLE through 
formation and deposition of immune complexes. A possible mechanism for this has been 
provided by Barrat et al who have demonstrated decreased levels of DNA methylation in 
SLE [155]. The significance of this is that methylation of human DNA is one of the 
mechanisms TLRs use to discriminate between host and foreign tissue. Therefore if the 
situation arose whereby human DNA failed to undergo methylation leading to the presence 
of hypomethylated DNA, this host DNA would have the ability to bind to and stimulate 
TLR9 leading to auto-antibody production. The correlation of the presence of this auto-
antibody with the increased expression of its receptor supports this thinking. The 
pathological link between increased endosomal TLR (3, 7, 8 & 9) expression and JSLE is a 
realistic pathway for autoimmune development with each receptor capable of detecting 
JSLE autoantigens leading to downstream stimulation of an autoimmune response against 
them. Our data support this hypothesis in JSLE. 
Many authors point to apoptosis as a mechanism for autoantigen exposure in SLE. The 
direct evidence behind this in terms of mechanistic pathway is however scarce. It is 
believed that increased apoptosis coupled with a decreased ability to clear apoptotic cells is 
resulting in the accumulation of late apoptotic and secondary necrotic cells leading to the 
exposure of host nuclear antigen [25]. This study clearly demonstrates that TLR activation 
leads to the production of IFN-α, thought to be a key player in the pathogenesis of JSLE. 
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Increased serum levels of IFN-α and the IFN-α gene signature exhibited by JSLE patients are 
thought to significantly contribute to the development and maintenance of autoimmunity 
through the chronic activation of autoreactive T and B cells [19]. However, data 
demonstrating the direct link between apoptosis, TLR activation and IFN-α are few until 
now.  
Immune complexes of SLE IgG and nucleic acid derived from necrotic and late apoptotic 
cells have been shown to induce IFN-α production through the TLR pathway [77, 107]. 
However this was carried out by inducing apoptosis through UV light exposure. Although 
useful in demonstrating the ability of apoptotic material to stimulate an autoimmune 
reaction it failed to shed any light on a potential source of this autoantigen in vivo. 
Neutropenia is a frequent occurrence in SLE and increased rates of apoptosis are thought 
to contribute to this [156]. Neutrophils account for up to 70% of the leukocyte population 
and excessive apoptosis of this cell could lead to a saturation of the body’s ability to clear 
the apoptotic cell debris. It has been found that there are increased levels of circulating 
apoptotic neutrophils in SLE which positively correlate with SLEDAI and dsDNA titres 
suggesting a tentative link between their presence and disease pathology [157-158]. These 
findings have been further validated in JSLE showing serum from JSLE patients to increase 
neutrophil apoptosis and this increased apoptosis was shown to positively correlate with 
disease activity and dsDNA concentration [24]. Not only this but it was found that there 
was in imbalance in the normal levels of pro-apoptotic and anti-apoptotic factors leaning 
towards increased neutrophil apoptosis [24]. The fact that apoptotic material has been 
shown to be capable of initiating an immune response and that neutrophils, the most 
abundant leukocyte, have been demonstrated to be present in high concentrations in an 
apoptotic state promotes them as an ideal candidate for the source of autoantigen in JSLE.  
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This present study strongly supports this theory, showing neutrophils that have undergone 
apoptosis in JSLE serum to be potent stimulators of IFN-α through activation of TLRs 3, 7, 8 
and 9. Confirmation that this stimulation is due to the presence of apoptotic neutrophils 
was demonstrated by a dose-response relationship to the concentration of incubated 
apoptotic neutrophil. This is believed to be through the detection of nucleic acids derived 
from the apoptotic neutrophils.  
To determine which TLRs played a dominant role, TLR expression of PBMCs incubated with 
apoptotic neutrophils was measured. It was found that TLRs 3, 7, 8 and 9 were all up-
regulated in these PBMCs, which had been obtained from control patients. This 
demonstrates that, even if not wholly responsible for the IFN-α production in response to 
apoptotic neutrophils, TLR up-regulation and stimulation are at least significantly 
associated with and therefore a likely contributor to this inflammatory response. As the 
experiment was carried out under controlled conditions the only influential variable on TLR 
expression was the presence of apoptotic neutrophils. As these particular TLRs are up-
regulated it can be indirectly postulated that nuclear proteins, such as that seen in JSLE, 
derived from apoptotic neutrophils, were again, at the very least, partially responsible for 
the inflammatory IFN-α response seen.  
The theory that IFN-α production is due to TLR activation by apoptosing neutrophils is 
further supported by our observation that TLR expression positively correlates with 
increasing apoptosis. This strengthens the association between the presence of apoptotic 
material and TLR activation. This study has shown that TLRs are capable of responding to 
nucleic acids derived from apoptotic neutrophils (as this was the only source) and that 
apoptotic neutrophils have the ability to increase TLR expression. This is directly relevant to 
JSLE in vivo linking the presence of apoptotic neutrophils to increased TLR expression and 
gives an explanation for the positive correlation seen with apoptotic neutrophil levels, TLR 
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expression and anti-dsDNA titres in JSLE [24, 32, 125]. The fact that all of these factors have 
been shown to be positively correlated with disease activity [24, 32, 125] suggests a 
pathway for inflammatory cytokine and auto-antibody production and more importantly a 
pathogenic mechanism for disease in JSLE.  
Hydroxychloroquine is a drug initially developed for malaria which was found to have an 
application in SLE. Its effect is thought to be due to its ability to prevent endosomal 
acidification and therefore inhibit the activation of TLRs 3, 7, 8 and 9. The effects of this 
drug have been mimicked in vivo in patients with SLE that have developed de novo 
signalling defects in the downstream signalling pathway for TLRs 7, 8 and 9 and have 
simultaneously entered clinical remission from SLE. It was found that the acquired 
signalling defect was present in the MyD88-dependent pathway [123]. In this present 
study, replication of this condition took place through an experiment using MyD88-
inihibition of TLR 7, 8 and 9 function. The data showed that blockage of these TLR pathway 
results in a decreased inflammatory response in TLR9-ligand stimulated PBMCs (x2.77 fold 
decrease) and importantly in PBMCs incubated with apoptotic neutrophils (x4.5 fold 
decrease). This provides solid evidence that TLRs 7, 8 and 9 are capable of inducing a 
downstream auto-inflammatory response in JSLE through activation by apoptosing 
neutrophils (as a source of nucleic autoantigens). 
The fact that IFN-α production was not reduced to control levels suggests that there may 
be other pathways involved. One explanation of this is that the IFN-α production could also 
be a result of TLR3 stimulation as this is a MyD88-independent pathway and therefore the 
actions of this receptor were not blocked in this assay. TRIF is an adapter protein specific to 
the downstream signalling pathway of TLR3, therefore performance of a TRIF inhibition 
assay could clarify this issue. It is also a possibility that IFN-α production is simultaneously 
being driven through TLR-independent DNA-reactive signalling pathways. For example, 
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retinoic acid-induced gene 1 (RIG-1) is a cytoplasmic protein capable of recognising dsRNA 
and stimulating an IFN-α response against it [159]. It is possible that this receptor and 
others like it may also play a role in the autoimmune response in JSLE. However, the 
significant reduction seen upon inhibition of MyD88 has identified another target protein 
for future therapies in SLE and JSLE and more work in this area is warranted. 
Given the evidence that TLR dysfunction has a pathological role in the autoimmune 
response in JSLE, it is thought that inhibition of their activity may confer therapeutic 
benefit. This led to a whole host of groups developing synthetic inhibitors of TLR activation 
[160-163]. Barrat et al found that by blocking TLR9 they could effectively block IFN-α 
production by pDCs, however stated that this may not be an effective therapeutic agent 
due to the TLR7 pathway remaining functional [164]. Through TLR inhibition they attributed 
IFN-α production in response to anti-dsDNA to TLR9 and IFN-α production in response to 
RNA-containing immune complexes to TLR7. Another rationale for the blockage of TLR7 
comes from the clinical observation of SLE flares to be associated with intercurrent 
infection [44]. TLR7 is responsible for the detection of virally derived ssRNA and is a potent 
inhibitor of IFN-α. Therefore, not targeting this pathway may still leave the patient open to 
disease relapse due to intercurrent viral infection.  
A dual inhibitor of both TLR7 and 9 has recently been developed which potently inhibits 
IFN-α produced by pDCs in response to DNA and RNA containing pathogens and immune 
complexes proven to promote serum IFN-α levels in SLE [77]. This agent is effective in 
mouse models of SLE with its use resulting in the suppression of autoantibody production, 
proteinuria and end organ pathology [164]. The present study demonstrating increased 
TLR7 expression in B cells suggests another, synergistic, therapeutic mechanism of this 
compound in JSLE through inhibition of antigen presentation of TLR7 ligands and further 
inhibition of autoantibodies produced through stimulation of this pathway in these cells, in 
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addition to pDCs. The specific mechanism of action for this inhibitory compound is 
unknown but it is likely that due to its dual effect that it blocks a common signalling 
pathway for the two receptors, for example MyD88. An application for this compound has 
been promoted by Guiducci et al who have performed a study assessing the effects of TLR 
activation of glucocorticod efficacy in SLE [165]. Glucocorticoids exhibit their anti-
inflammatory effects through inhibition of NF-ĸB which leads to inhibition of inflammatory 
cytokine production, including IFN-α, and eventual cell death. Their study found that TLR 
activation of pDCs conferred protection against glucocorticoid-induced cell death and IFN-α 
inhibition. Using the TLR7 and 9 dual inhibitor developed by Barrat et al they demonstrated 
that inhibition of these TLRs increases the sensitivity of pDCs to glucocorticoid induced cell 
death [153]. This has major implications for SLE as a whole but is of particular importance 
to JSLE. The fact that the use of TLR inhibitors may be employed to increase sensitivity of 
lupus patients to glucocorticoids means that these particularly harmful medications will be 
more effective at lower doses therefore the steroid burden suffered by these patients may 
be significantly reduced. This is particularly relevant to JSLE patients who suffer more 
severe illness and therefore require proportionally higher doses of steroids over a longer 
disease duration consequently suffering the more severe treatment related morbidity. A 
notable benefit of this will be the positive effects decreased steroid burden could have on 
normal pubertal development, through a dual effect of decreased steroids and improved 
disease status. This work is extremely encouraging and our work confirming that TLR 
inhibition does have an anti-inflammatory effect in JSLE suggests practical applications for 
this therapy in JSLE.  
Hydroxychloroquine is a drug initially developed as an anti-parasitic for the treatment of 
malaria. However an observation was made that anti-malarials improved rheumatic 
symptoms in those with rheumatoid arthritis or SLE [166]. One theory for this outcome is 
that it works by reducing endosomal pH, inhibiting innate immune activation through 
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inhibition of the endosomal TLRs 3, 7-9 [167]. It has since been shown to be effective in 
SLE, reducing disease severity, increasing time between relapse and decreasing risk of 
complications [168-172]. This supports our theory showing TLRs to be important in 
promoting and maintaining disease in lupus and that inhibition of their effect may reduce 
disease severity. Hydroxychloroquine also confers benefits outside of the effects of TLR 
inhibition, strengthening its case. The major benefit being a reduced risk of cardiovascular 
events, the leading cause of fatality in lupus [169]. This is thought to contribute to the 50% 
increased survival of those that have been treated with hydroxychloroquine [169, 173]. 
Despite this only 40-50% of patients receive hydroxychloroquine [167]. It has been 
proposed that due to the cost-efficiency and favourable safety profile that all patients 
should receive this therapy despite disease severity or additional medications [174]. The 
irony of focusing on advancing therapies is that sometimes old therapies, proven to be 
effective, can be forgotten about or perceived as inferior due to their heritage. With 
current research focusing on TLRs and the effects that inhibiting them can have, the very 
first TLR inhibitor seems to have been lost in history. Recent evidence, including ours 
showing TLR blockade to be effective in inhibiting an inflammatory response, suggest that 
this old drug still has a therapeutic role in lupus and its application should be promoted 
among clinicians [168-173]. 
Our work has confirmed some of the findings in adult-onset SLE in the juvenile population 
and have identified apoptotic neutrophils as a likely source of nuclear autoantigen. It is 
thought that adult and juvenile-onset disease share a similar aetiopathology and our 
findings confirm this, however there are clear differences in clinical manifestation with JSLE 
patients suffering more severe illness. Despite this, significant paucity of studies 
investigating the immunopathology of JSLE underline the pressing need for research in 
JSLE. Immunological dysregulation is likely to be more obvious in those with more 
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pronounced disease and severe phenotype. Therefore by studying JSLE patients it may be 
easier to unpick the complexities of the disease hastening therapeutics advancements.    
4.1.4 Limitations of Study 
This study aimed at undertaking a robust investigation of the role of TLRs in JSLE. Some 
important limitations of the study methodology and project, however, need to be noted.  
JSLE and JIA patients studied had a range of disease activity and were all being treated with 
different therapeutic agents at varying doses. As we have shown that TLR expression may 
be influenced by the concentration of autoantigen available it is believed that disease 
activity may have an influence on the analysis of TLR expression. Therapeutics are 
specifically deployed to manipulate the immune system and it would be unwise to assume 
that this would not affect any analysis of these patients. The number of patients in this 
study precluded a formal analysis investigating the affect of disease activity and treatment 
on TLR expression/activation. This would be prudent for future studies. However as both 
groups were receiving therapy we believe this will not have had a significant effect on the 
results obtained. 
The most significant challenge to the study of the immunopathogenesis of JSLE lies innately 
with condition itself. Its complexity, diversity, and rarity make it difficult to secure samples 
sizes sufficient enough for statistical power. In addition to this, diversity of phenotype and 
treatment course can act as confounders in the data presented and conclusions drawn 
from this and other studies. However, this obstacle lends itself to the need of collaboration 
in studying JSLE, which if significant progression in the understanding JSLE is going to be 
made, is required.  
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4.1.5 Strengths of the Study 
This study has generated important data on the role of TLRs in the aetiopathogenesis of 
JSLE, and especially the importance of apoptotic neutrophils as a likely source of nuclear 
autoantigens in triggering the immune response. Importantly, this study: 
 Has successfully undertaken a robust and competent piece of hypothesis-led basic 
science research in a rare and complex, archetypal systemic autoimmune disorder of 
childhood 
 It demonstrates consistency with the latest scientific evidence base in this field, as well 
as adding significantly to this growing body of evidence supporting the role of TLRs in 
detecting SLE autoantigens  
 It provides important supportive evidence for the use of TLR inhibitors in the treatment 
of lupus 
 It is unique in being the first study to demonstrate increased TLR expression in JSLE  
 It provides important data in support of a mechanistic pathway of how apoptotic 
neutrophils are likely to act as source of nucleic autoantigen in JSLE 
Published data studying the immunopathogenesis of JSLE is scarce, and to date, published 
data on TLR expression in JSLE does not exist. This study is the first description of abnormal 
TLR homeostasis and the significant role they play in the recognition of likely autoantigens 
in JSLE. Research in JSLE is lagging far behind those working in the adult field, for a 
condition with no cure, limited treatment options and a more severe disease phenotype 
over a longer disease duration. There is therefore a pressing need for research in children. 
This thesis therefore aims to go some way in contributing to this challenge, although much 
more work is required.  
94 
 
4.1.6 Further Work 
Having identified some of the limitations of the study, and significant benefits, what is clear 
is that the data generated, and the methodology used raises many exciting avenues ahead 
for future research in this field. These include: 
 Measuring TLR protein expression in B cells – This was tried repeatedly using flow 
cytometry in detail, refining assays and experimental techniques. Problems arose due 
to the use of unconjugated B cell and TLR antibodies. This necessitated the 
performance of numerous washing and conjugating steps which were thought to be 
the reason for the failure of this assay. The purchase of fluorochrome conjugated B cell 
and TLR antibodies may have allowed the analysis of TLR protein expression in B cells 
and this would be a useful step to re-affirm our findings.  
 The TLR inhibitor employed in our inhibition assay was specific for a downstream 
signaller common to TLRs 7, 8 and 9. Although this had a clear benefit of blocking all 
three of these TLRs as a proof-of-concept study, it did not allow the attribution of 
responsibility between these TLRs. It may be the case, for example, that TLR8 is not a 
significant player in this autoimmune response in JSLE, as suggested by Guiducci et al in 
adult-onset SLE [165]. However we cannot make this assumption in JSLE and would like 
to test this hypothesis. By deducing the significance of each TLR in this auto-immune 
response we could ascertain the ideal combination of TLR inhibition in preventing or 
reducing this auto-inflammatory response in JSLE. The use of a TRIF-inhibitory peptide 
would be one method of doing this by blocking TLR3 activation. 
 The residual IFN-α production seen after MyD88 inhibition of TLR stimulated cells may 
be due to TLR3 stimulation, as this pathway wasn’t blocked using MyD88. At the same 
time, TLR-independent pathways may also be responsible. For example, the RIG-1 
pathway, mentioned earlier, has been identified as being capable of producing IFN-α in 
response to DNA binding. It would be interesting to ascertain, through inhibition 
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assays, whether this pathway has a role in the residual IFN-α produced post TLR 
blockade and may identify another target for therapy in SLE.  
 A longitudinal assessment of TLR expression in a cohort of JSLE patients would provide 
important and more detailed assessment of the association between TLR expression 
and disease flare. The present study is cross sectional using data taken from different 
patients at a single point in time. This type of measurement doesn’t take into account 
difference of baseline TLR expression between patients, and effects of disease course, 
activity and treatment on these parameters. Therefore studying a group of the same 
patients over time will provide a more accurate assessment of this association.   
 Guiducci et al made the interesting observation that activation of NF-ĸB is responsible 
for the protection afforded to TLR-activated pDCs against glucocorticoid-induced cell 
death [165]. They demonstrated that inhibition of this protein achieved the same 
benefits as blockage of the TLR7 and 9 pathways. Research into cancer has identified 
dysregulated NF-ĸB activity as a possible cause with persistent activation shown to 
have unfavourable effects on cell proliferation, migration and apoptosis [175]. 
Genistein is a natural compound found to be a highly effective NF-ĸB inhibitor and 
clinical trials have shown it to be of benefit in haematological malignancies as well as 
breast, prostate, pancreatic, melanoma and kidney cancers. The activity of NF-ĸB also 
seems to have a significant effect in the pathogenesis of SLE. Therefore it seems likely 
that there may be potential scope for use of this inhibitor in SLE. Research with these 
as yet unused drugs in SLE may prove fruitful.   
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5 Conclusions  
To conclude, this study has demonstrated increased expression of TLRs 3, 8 and 9 in JSLE 
PBMCs and TLR 7 and 9 in B cells, consistent with findings in adult-onset SLE and have 
alluded to the future benefit this may infer on recently developed therapeutic TLR 
inhibitors. We have demonstrated IFN-α production in response to TLR stimulation and 
using this criteria have been the first to reveal apoptotic neutrophils as potent stimulators 
of TLRs and therefore a likely source of nucleic autoantigens in JSLE. The expression of TLRs 
was found to be dependent upon both the dose of apoptotic neutrophil and the 
percentage apoptosis of neutrophil provided. Finally we found that inhibition of TLRs 7, 8 
and 9 led to a decrease in an IFN-α inflammatory response in the presence of TLR9 
stimulation and an auto-inflammatory response in the presence of apoptotic neutrophils.  
In a time with exciting new prospects for potential new therapeutics in adult-onset SLE we 
are the first to report any evidence supporting the role of TLRs in JSLE. By doing this we 
have made a case for utilising TLR inhibition therapy in JSLE and hope to see the application 
of this if found to be of clinical benefit.   
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Appendix 1: PBMC TLR Expression 
Group 
TLR3 Protein 
Expression 
TLR8 Protein 
Expression 
TLR9 Protein 
Expression 
Control 1 22.7 11.5 14.1 
Control 2 14.5 7.52 10.5 
Control 3 16.2 16.3 7.61 
Control 4 14.5 18.1 5.48 
Control 5 18.3 13.3 16.9 
JSLE 1 52.1 55.1 59.7 
JSLE 2 91.2 61.1 35.6 
JSLE 3 123 73.9 93.4 
JSLE 4 83.1 73.4 57.3 
JSLE 5 58 51.7 101 
JIA 1 40.8 24.9 14.4 
JIA 2 36.9 29.1 9.05 
JIA 3 34.2 27.3 26.4 
JIA 4 26.8 33.1 12.8 
JIA 5 53.3 15.8 9.54 
 
Raw data shown from Figure 19 
Control = Paediatric Control Group 
JSLE = Juvenile-onset Systemic Lupus Erythematosus Group 
JIA = Juvenile Idiopathic Arthritis Group 
1-5 denotes sample number   
105 
 
Appendix 2: B Cell TLR mRNA Expression  
 
Group 
TLR3 mRNA 
Expression 
TLR7 mRNA 
Expression 
TLR8 mRNA 
Expression 
TLR9 mRNA 
Expression 
Control 1 0.797087 2.410194 0.215858 1.268608 
Control 2 0.433247 0.774719 0.866667 0.535152 
Control 3 3.942119 3.66073 8.663402 4.449688 
Control 4 0.818511 1.020048 1.058034 1.15315 
JIA 1 0.592613 0.622381 0.861632 0.84344 
JIA 2 0.881454 0.926062 0.944699 0.780629 
JIA 3 0.96339 0.516048 0.640421 0.863089 
JIA 4 0.802806 0.737518 0.365066 0.920236 
JIA 5 0.991693 1.119936 2.023213 1.712563 
JIA 6 0.490006 0.465022 0.551843 0.590256 
JIA 7 0.151112 0.403848 0.244799 0.411064 
JSLE 1 0.381954 0.653887 0.869116 1.16209 
JSLE 2 0.632261 1.022084 0.68987 0.577532 
JSLE 3 1.786284 2.40312 2.954282 1.838171 
JSLE 4 15.91362 17.49169 17.39203 20.01661 
JSLE 5 1.595034 0.809503 0.575856 1.214041 
JSLE 6 0.569133 0.708229 0.733167 0.768634 
JSLE 7 1.65056 1.42443 2.153073 2.03131 
 
Raw data shown from Figure 20 
Control = Paediatric Control Group 
JSLE = Juvenile-onset Systemic Lupus Erythematosus Group 
JIA = Juvenile Idiopathic Arthritis Group 
Number following group denotes sample number 
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Appendix 3: IFN-α Protein Expression in TLR Agonist 
Stimulated PBMCs 
 
Sample IFN-α Protein Expression 
Unstimulated PBMCs 1 176.8182 
Unstimulated PBMCs 2 158.6364 
Unstimulated PBMCs 3 133.6364 
Unstimulated PBMCs 4 142.7273 
TLR3 1 260.9091 
TLR3 2 199.5455 
TLR3 3 138.1818 
TLR3 4 158.6364 
TLR7 1 133.6364 
TLR7 2 158.6364 
TLR7 3 197.2727 
TLR7 4 145 
TLR8 1 215.4545 
TLR8 2 172.2727 
TLR8 3 188.1818 
TLR8 4 163.1818 
TLR9 1 151.8182 
TLR9 2 160.9091 
TLR9 3 185.9091 
TLR9 4 267.7273 
 
Raw data shown from Figure 21 B 
Unstimulated PBMCs = PBMCs with no TLR agonist added 
TLR3 = PBMCs incubated with TLR3 agonist 
TLR7 = PBMCs incubated with TLR7 agonist  
TLR8 = PBMCs incubated with TLR8 agonist  
TLR9 = PBMCs incubated with TLR9 agonist  
Number after condition denotes sample number 
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Appendix 4: MyD88 TLR Inhibition Decreases TLR Induced IFN-
α Production in PBMCs 
 
Group IFN-α mRNA Expression 
Unstimulated PBMCs 1 0.082165 
Unstimulated PBMCs 2 0.030211 
Unstimulated PBMCs 3 0.033126 
Unstimulated PBMCs 4 0.079353 
Unstimulated PBMCs 5 0.058853 
TLR9-MyD88 1 2.290263 
TLR9-MyD88 2 0.595437 
TLR9-MyD88 3 0.272631 
TLR9-MyD88 4 0.732064 
TLR9-MyD88 5 0.557341 
TLR9+ MyD88 1 0.701947 
TLR9+ MyD88 2 0.166522 
TLR9+ MyD88 3 0.042891 
TLR9+ MyD88 4 0.187589 
TLR9+ MyD88 5 0.201109 
AN-MyD88 1 1.165025 
AN-MyD88 2 1.603865 
AN-MyD88 3 75.46326 
AN-MyD88 4 7.943016 
AN-MyD88 5 0.789189 
AN+MyD88 1 0.354161 
AN+MyD88 2 0.346981 
AN+MyD88 3 17.87349 
AN+MyD88 4 0.382292 
AN+MyD88 5 0.383664 
 
Raw data shown from Figure 28 & 29 
Unstimulated PBMCs = PBMCs with no TLR agonist added 
TLR3 = PBMCs incubated with TLR3 agonist 
TLR7 = PBMCs incubated with TLR7 agonist  
TLR8 = PBMCs incubated with TLR8 agonist  
TLR9 = PBMCs incubated with TLR9 agonist  
Number after condition denotes sample number 
